{"fetched":"2026-10-26","previousFetched":"2026-10-19","keepDays":90,"changes":[{"detected":"2026-10-26","drugId":"midostaurin","nct":"NCT00651261","title":"Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phases":["PHASE3"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2016-07","kind":"status","from":"UNKNOWN","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"denosumab","nct":"NCT02051218","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","phases":["PHASE3"],"sponsor":"Swiss Cancer Institute","primaryCompletion":"2026-03-20","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-26","drugId":"denosumab","nct":"NCT02051218","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","phases":["PHASE3"],"sponsor":"Swiss Cancer Institute","primaryCompletion":"2026-03-20","kind":"primary-completion","from":"2026-06-30","to":"2026-03-20"},{"detected":"2026-10-26","drugId":"capivasertib","nct":"NCT02523014","title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","phases":["PHASE2"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2028-06-01","kind":"primary-completion","from":"2027-01-01","to":"2028-06-01"},{"detected":"2026-10-26","drugId":"epirubicin","nct":"NCT03036488","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2025-10-14","kind":"results-posted"},{"detected":"2026-10-26","drugId":"inotuzumab-ozogamicin","nct":"NCT03150693","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","phases":["PHASE3"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2027-11-01","kind":"primary-completion","from":"2027-03-01","to":"2027-11-01"},{"detected":"2026-10-26","drugId":"ql2107","nct":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phases":["PHASE3"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-01-01","kind":"primary-completion","from":"2026-10-31","to":"2027-01-01"},{"detected":"2026-10-26","drugId":"ino-5401","nct":"NCT03491683","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","phases":["PHASE1","PHASE2"],"sponsor":"Inovio Pharmaceuticals","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2026-12-31","to":"2027-12-31"},{"detected":"2026-10-26","drugId":"envafolimab","nct":"NCT03667170","title":"KN035 for dMMR/MSI-H Advanced Solid Tumors","phases":["PHASE2"],"sponsor":"3D Medicines (Sichuan) Co., Ltd.","primaryCompletion":"2026-12-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"talazoparib","nct":"NCT03672773","title":"Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Jonsson Comprehensive Cancer Center","primaryCompletion":"2027-10-01","kind":"primary-completion","from":"2026-10-01","to":"2027-10-01"},{"detected":"2026-10-26","drugId":"bcg-intravesical","nct":"NCT03711032","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2028-07-31","kind":"primary-completion","from":"2026-07-31","to":"2028-07-31"},{"detected":"2026-10-26","drugId":"belantamab-mafodotin","nct":"NCT03715478","title":"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex","phases":["PHASE1","PHASE2"],"sponsor":"Canadian Myeloma Research Group","primaryCompletion":"2027-06-01","kind":"primary-completion","from":"2025-06-01","to":"2027-06-01"},{"detected":"2026-10-26","drugId":"busulfan","nct":"NCT03970096","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","phases":["PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2028-12-31","kind":"primary-completion","from":"2027-12-31","to":"2028-12-31"},{"detected":"2026-10-26","drugId":"cladribine","nct":"NCT04047628","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","phases":["PHASE3"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2030-08-06","kind":"primary-completion","from":"2026-10","to":"2030-08-06"},{"detected":"2026-10-26","drugId":"mobocertinib","nct":"NCT04129502","title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","phases":["PHASE3"],"sponsor":"Takeda","primaryCompletion":"2026-09-22","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"mobocertinib","nct":"NCT04129502","title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","phases":["PHASE3"],"sponsor":"Takeda","primaryCompletion":"2026-09-22","kind":"primary-completion","from":"2026-10-31","to":"2026-09-22"},{"detected":"2026-10-26","drugId":"cobolimab","nct":"NCT04139902","title":"Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma","phases":["PHASE2"],"sponsor":"Diwakar Davar","primaryCompletion":"2025-09-29","kind":"results-posted"},{"detected":"2026-10-26","drugId":"ql2107","nct":"NCT04267848","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","phases":["PHASE3"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2030-01-31","kind":"primary-completion","from":"2027-01-31","to":"2030-01-31"},{"detected":"2026-10-26","drugId":"alemtuzumab","nct":"NCT04339777","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-10-01","kind":"primary-completion","from":"2026-10-01","to":"2028-10-01"},{"detected":"2026-10-26","drugId":"enzalutamide","nct":"NCT04557449","title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2029-10-07","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"enzalutamide","nct":"NCT04557449","title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2029-10-07","kind":"primary-completion","from":"2026-09-23","to":"2029-10-07"},{"detected":"2026-10-26","drugId":"giredestrant","nct":"NCT04557449","title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2029-10-07","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"acalabrutinib","nct":"NCT04604067","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","phases":["PHASE2"],"sponsor":"Swiss Cancer Institute","primaryCompletion":"2029-01-30","kind":"primary-completion","from":"2026-07-30","to":"2029-01-30"},{"detected":"2026-10-26","drugId":"pf-07248144","nct":"NCT04606446","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","phases":["PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2029-08-27","kind":"primary-completion","from":"2029-07-13","to":"2029-08-27"},{"detected":"2026-10-26","drugId":"elranatamab","nct":"NCT04649359","title":"MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb","phases":["PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2022-06-17","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"parsaclisib","nct":"NCT04661007","title":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","phases":["PHASE1","PHASE2"],"sponsor":"Incyte Biosciences Japan GK","primaryCompletion":"2025-07-01","kind":"results-posted"},{"detected":"2026-10-26","drugId":"fludeoxyglucose-f18","nct":"NCT04665739","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2032-09-01","kind":"primary-completion","from":"2027-07-01","to":"2032-09-01"},{"detected":"2026-10-26","drugId":"domvanalimab","nct":"NCT04736173","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","phases":["PHASE2"],"sponsor":"Arcus Biosciences, Inc.","primaryCompletion":"2026-09-17","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"domvanalimab","nct":"NCT04736173","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","phases":["PHASE2"],"sponsor":"Arcus Biosciences, Inc.","primaryCompletion":"2026-09-17","kind":"primary-completion","from":"2027-05","to":"2026-09-17"},{"detected":"2026-10-26","drugId":"isatuximab","nct":"NCT04786028","title":"A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM","phases":["PHASE2"],"sponsor":"Canadian Myeloma Research Group","primaryCompletion":"2028-12","kind":"primary-completion","from":"2026-03","to":"2028-12"},{"detected":"2026-10-26","drugId":"apalutamide","nct":"NCT04787744","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","phases":["PHASE2","PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-10-02","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"apalutamide","nct":"NCT04787744","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","phases":["PHASE2","PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-10-02","kind":"primary-completion","from":"2026-09-30","to":"2026-10-02"},{"detected":"2026-10-26","drugId":"talazoparib","nct":"NCT04824937","title":"Telaglenastat + Talazoparib In Prostate Cancer","phases":["PHASE2"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2021-12-31","kind":"status","from":"UNKNOWN","to":"WITHDRAWN"},{"detected":"2026-10-26","drugId":"tocilizumab","nct":"NCT04876534","title":"Tocilizumab in Active Moderate-severe Graves' Orbitopathy","phases":["PHASE2"],"sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","primaryCompletion":"2023-09-30","kind":"status","from":"UNKNOWN","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"tocilizumab","nct":"NCT04876534","title":"Tocilizumab in Active Moderate-severe Graves' Orbitopathy","phases":["PHASE2"],"sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","primaryCompletion":"2023-09-30","kind":"primary-completion","from":"2022-12-18","to":"2023-09-30"},{"detected":"2026-10-26","drugId":"floxuridine","nct":"NCT04898504","title":"HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.","phases":["PHASE2"],"sponsor":"Oslo University Hospital","primaryCompletion":"2026-08-20","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-26","drugId":"floxuridine","nct":"NCT04898504","title":"HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.","phases":["PHASE2"],"sponsor":"Oslo University Hospital","primaryCompletion":"2026-08-20","kind":"primary-completion","from":"2025-05","to":"2026-08-20"},{"detected":"2026-10-26","drugId":"mifepristone","nct":"NCT05076682","title":"Reverse Triple Negative Immune Resistant Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"ibrutinib","nct":"NCT05105841","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","phases":["PHASE2"],"sponsor":"AbbVie","primaryCompletion":"2025-10-09","kind":"results-posted"},{"detected":"2026-10-26","drugId":"penpulimab","nct":"NCT05137171","title":"AK105 Combined With Anlotinib in Patients With Cervical Cancer","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital of Zhengzhou University","primaryCompletion":"2025-07-01","kind":"status","from":"UNKNOWN","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"penpulimab","nct":"NCT05137171","title":"AK105 Combined With Anlotinib in Patients With Cervical Cancer","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital of Zhengzhou University","primaryCompletion":"2025-07-01","kind":"primary-completion","from":"2024-03-01","to":"2025-07-01"},{"detected":"2026-10-26","drugId":"rusfertide","nct":"NCT05210790","title":"A Study of Rusfertide in Adults With Polycythemia Vera (PV)","phases":["PHASE3"],"sponsor":"Protagonist Therapeutics, Inc.","primaryCompletion":"2025-02-21","kind":"results-posted"},{"detected":"2026-10-26","drugId":"imiquimod","nct":"NCT05212246","title":"Basal Cell Carcinoma Chemoprevention Trial","phases":["PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2032-10-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"imiquimod","nct":"NCT05212246","title":"Basal Cell Carcinoma Chemoprevention Trial","phases":["PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2032-10-06","kind":"primary-completion","from":"2032-10-05","to":"2032-10-06"},{"detected":"2026-10-26","drugId":"megestrol","nct":"NCT05247268","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-03-10","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"lutathera","nct":"NCT05247905","title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial","phases":["PHASE2"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2027-10-01","kind":"primary-completion","from":"2028-03-31","to":"2027-10-01"},{"detected":"2026-10-26","drugId":"bgb-16673","nct":"NCT05294731","title":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2029-01-31","to":"2027-06-30"},{"detected":"2026-10-26","drugId":"jdq443","nct":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phases":["PHASE1","PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2026-09-28","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-26","drugId":"jdq443","nct":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phases":["PHASE1","PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2026-09-28","kind":"primary-completion","from":"2026-09-30","to":"2026-09-28"},{"detected":"2026-10-26","drugId":"radioactive-iodine","nct":"NCT05468554","title":"Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer","phases":["PHASE3"],"sponsor":"Medical University of Bialystok","primaryCompletion":"2028-01-31","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"radioactive-iodine","nct":"NCT05468554","title":"Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer","phases":["PHASE3"],"sponsor":"Medical University of Bialystok","primaryCompletion":"2028-01-31","kind":"primary-completion","from":"2026-04-30","to":"2028-01-31"},{"detected":"2026-10-26","drugId":"balstilimab","nct":"NCT05529316","title":"A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma","phases":["PHASE2"],"sponsor":"Agenus Inc.","primaryCompletion":"2026-04-27","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-26","drugId":"balstilimab","nct":"NCT05529316","title":"A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma","phases":["PHASE2"],"sponsor":"Agenus Inc.","primaryCompletion":"2026-04-27","kind":"primary-completion","from":"2028-02","to":"2026-04-27"},{"detected":"2026-10-26","drugId":"metyrapone","nct":"NCT05563467","title":"Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.","phases":["PHASE2"],"sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","primaryCompletion":"2027-05-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"binimetinib","nct":"NCT05564403","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-08-08","kind":"primary-completion","from":"2026-10-01","to":"2026-08-08"},{"detected":"2026-10-26","drugId":"dabrafenib","nct":"NCT05585320","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Immuneering Corporation","primaryCompletion":"2027-06","kind":"primary-completion","from":"2026-06","to":"2027-06"},{"detected":"2026-10-26","drugId":"oregovomab","nct":"NCT05605535","title":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","phases":["PHASE2"],"sponsor":"CanariaBio Inc.","primaryCompletion":"2027-05-15","kind":"primary-completion","from":"2026-10-15","to":"2027-05-15"},{"detected":"2026-10-26","drugId":"emavusertib","nct":"NCT05669352","title":"CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases","phases":["PHASE1","PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-11","kind":"new-study","to":"SUSPENDED"},{"detected":"2026-10-26","drugId":"daratumumab","nct":"NCT05671757","title":"Daratumumab in Primary Antiphospholipid Syndrome","phases":["PHASE1","PHASE2"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2028-05-05","kind":"primary-completion","from":"2026-10-16","to":"2028-05-05"},{"detected":"2026-10-26","drugId":"isatuximab","nct":"NCT05690984","title":"Elimination of Minimal Residual Disease After Transplant","phases":["PHASE2"],"sponsor":"Medical College of Wisconsin","primaryCompletion":"2026-08-19","kind":"primary-completion","from":"2026-09","to":"2026-08-19"},{"detected":"2026-10-26","drugId":"cemiplimab","nct":"NCT05694871","title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","phases":["PHASE2"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2028-04-07","kind":"primary-completion","from":"2027-05-31","to":"2028-04-07"},{"detected":"2026-10-26","drugId":"larotrectinib","nct":"NCT05783323","title":"Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","phases":["PHASE2"],"sponsor":"Children's Hospital of Philadelphia","primaryCompletion":"2028-10-01","kind":"primary-completion","from":"2026-10-01","to":"2028-10-01"},{"detected":"2026-10-26","drugId":"ribociclib","nct":"NCT05827081","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","phases":["PHASE3"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2029-09-07","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"eltrombopag","nct":"NCT05907499","title":"Decitabine for Poor Graft Function Post Allo-HSCT","phases":["PHASE3"],"sponsor":"The First Affiliated Hospital of Soochow University","primaryCompletion":"2026-01-01","kind":"status","from":"NOT_YET_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"eltrombopag","nct":"NCT05907499","title":"Decitabine for Poor Graft Function Post Allo-HSCT","phases":["PHASE3"],"sponsor":"The First Affiliated Hospital of Soochow University","primaryCompletion":"2026-01-01","kind":"results-posted"},{"detected":"2026-10-26","drugId":"eltrombopag","nct":"NCT05907499","title":"Decitabine for Poor Graft Function Post Allo-HSCT","phases":["PHASE3"],"sponsor":"The First Affiliated Hospital of Soochow University","primaryCompletion":"2026-01-01","kind":"primary-completion","from":"2026-07-01","to":"2026-01-01"},{"detected":"2026-10-26","drugId":"benmelstobart","nct":"NCT05934331","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","phases":["PHASE2"],"sponsor":"LaNova Medicines Zhejiang Co., Ltd.","primaryCompletion":"2031-08-06","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"lm-302","nct":"NCT05934331","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","phases":["PHASE2"],"sponsor":"LaNova Medicines Zhejiang Co., Ltd.","primaryCompletion":"2031-08-06","kind":"primary-completion","from":"2026-07-01","to":"2031-08-06"},{"detected":"2026-10-26","drugId":"inlexisertib","nct":"NCT05957367","title":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Deciphera Pharmaceuticals, LLC","primaryCompletion":"2027-03","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"apalutamide","nct":"NCT05960578","title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2025-07-29","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-26","drugId":"apalutamide","nct":"NCT05960578","title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2025-07-29","kind":"results-posted"},{"detected":"2026-10-26","drugId":"iberdomide","nct":"NCT06179888","title":"Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2030-03-01","kind":"primary-completion","from":"2027-10-31","to":"2030-03-01"},{"detected":"2026-10-26","drugId":"azd8421","nct":"NCT06188520","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2027-08-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"budigalimab","nct":"NCT06236438","title":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2031-10","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"eribulin","nct":"NCT06279364","title":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","phases":["PHASE3"],"sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","primaryCompletion":"2027-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"eribulin","nct":"NCT06279364","title":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","phases":["PHASE3"],"sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","primaryCompletion":"2027-04","kind":"primary-completion","from":"2026-07","to":"2027-04"},{"detected":"2026-10-26","drugId":"zg006","nct":"NCT06283719","title":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","primaryCompletion":"2027-04","kind":"primary-completion","from":"2026-04","to":"2027-04"},{"detected":"2026-10-26","drugId":"lomustine","nct":"NCT06325683","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-07-15","kind":"primary-completion","from":"2028-07-15","to":"2029-07-15"},{"detected":"2026-10-26","drugId":"mitomycin","nct":"NCT06331299","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","phases":["PHASE3"],"sponsor":"UroGen Pharma Ltd.","primaryCompletion":"2025-09-11","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"sacituzumab-tirumotecan","nct":"NCT06356311","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-10-19","kind":"primary-completion","from":"2027-01-04","to":"2026-10-19"},{"detected":"2026-10-26","drugId":"ipilimumab","nct":"NCT06365619","title":"Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2026-10","kind":"status","from":"RECRUITING","to":"WITHDRAWN"},{"detected":"2026-10-26","drugId":"ipilimumab","nct":"NCT06365619","title":"Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2026-10","kind":"primary-completion","from":"2027-08","to":"2026-10"},{"detected":"2026-10-26","drugId":"chiauranib","nct":"NCT06492915","title":"Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma","phases":["PHASE2"],"sponsor":"Chipscreen Biosciences, Ltd.","primaryCompletion":"2027-02-28","kind":"primary-completion","from":"2026-05-31","to":"2027-02-28"},{"detected":"2026-10-26","drugId":"elritercept","nct":"NCT06499285","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","phases":["PHASE3"],"sponsor":"Takeda","primaryCompletion":"2028-09-15","kind":"primary-completion","from":"2028-05-01","to":"2028-09-15"},{"detected":"2026-10-26","drugId":"nadofaragene-firadenovec","nct":"NCT06510374","title":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","phases":["PHASE3"],"sponsor":"Ferring Pharmaceuticals","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2028-06-30","to":"2028-09-30"},{"detected":"2026-10-26","drugId":"ql2107","nct":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phases":["PHASE3"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2032-12-25","kind":"primary-completion","from":"2029-11-30","to":"2032-12-25"},{"detected":"2026-10-26","drugId":"serplulimab","nct":"NCT06601309","title":"Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC","phases":["PHASE2"],"sponsor":"Fujian Medical University Union Hospital","primaryCompletion":"2027-03-31","kind":"primary-completion","from":"2026-07-01","to":"2027-03-31"},{"detected":"2026-10-26","drugId":"pm8002","nct":"NCT06616532","title":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Biotheus Inc.","primaryCompletion":"2027-05","kind":"primary-completion","from":"2027-01-25","to":"2027-05"},{"detected":"2026-10-26","drugId":"inbrx-106","nct":"NCT06623136","title":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Elpiscience (Suzhou) Biopharma, Ltd.","primaryCompletion":"2027-02-28","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"patritumab-deruxtecan","nct":"NCT06686394","title":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-08-02","kind":"primary-completion","from":"2030-04-18","to":"2032-08-02"},{"detected":"2026-10-26","drugId":"xnw5004","nct":"NCT06702995","title":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Evopoint Biosciences Inc.","primaryCompletion":"2027-07-13","kind":"primary-completion","from":"2026-05-13","to":"2027-07-13"},{"detected":"2026-10-26","drugId":"denosumab","nct":"NCT06706414","title":"NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia","phases":["PHASE1","PHASE2"],"sponsor":"Martin Blomberg Jensen","primaryCompletion":"2026-04-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"denosumab","nct":"NCT06706414","title":"NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia","phases":["PHASE1","PHASE2"],"sponsor":"Martin Blomberg Jensen","primaryCompletion":"2026-04-30","kind":"primary-completion","from":"2026-08","to":"2026-04-30"},{"detected":"2026-10-26","drugId":"befotertinib","nct":"NCT06728865","title":"Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study","phases":["PHASE2"],"sponsor":"Li-kun Chen","primaryCompletion":"2028-02-01","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"furmonertinib","nct":"NCT06728865","title":"Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study","phases":["PHASE2"],"sponsor":"Li-kun Chen","primaryCompletion":"2028-02-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"vorolanib","nct":"NCT06730672","title":"An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus","phases":["PHASE2"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2027-12-27","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"iberdomide","nct":"NCT06762769","title":"Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2032-11-01","kind":"primary-completion","from":"2032-11","to":"2032-11-01"},{"detected":"2026-10-26","drugId":"ivonescimab","nct":"NCT06805617","title":"A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers","phases":["PHASE2"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2027-07-01","kind":"primary-completion","from":"2026-07-01","to":"2027-07-01"},{"detected":"2026-10-26","drugId":"raltitrexed","nct":"NCT06841159","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-09-30","kind":"primary-completion","from":"2026-03-01","to":"2029-09-30"},{"detected":"2026-10-26","drugId":"izalontamab-brengitecan","nct":"NCT06857175","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","phases":["PHASE3"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"hs-20093","nct":"NCT06935409","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2026-06-17","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-26","drugId":"ga68-psma-11","nct":"NCT07052214","title":"PSMA PET Combined With MRI for the Detection of PCa","phases":["PHASE3"],"sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","primaryCompletion":"2027-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"ql2107","nct":"NCT07162883","title":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","phases":["PHASE3"],"sponsor":"Qilu Pharmaceutical Co., Ltd.","primaryCompletion":"2026-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"altretamine","nct":"NCT07183371","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","phases":["PHASE2"],"sponsor":"University of Oxford","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-12","to":"2027-03"},{"detected":"2026-10-26","drugId":"tovorafenib","nct":"NCT07206849","title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","phases":["PHASE2"],"sponsor":"Nationwide Children's Hospital","primaryCompletion":"2030-02","kind":"primary-completion","from":"2030-11","to":"2030-02"},{"detected":"2026-10-26","drugId":"bcg-intravesical","nct":"NCT07222488","title":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2027-07-30","kind":"primary-completion","from":"2029-02-28","to":"2027-07-30"},{"detected":"2026-10-26","drugId":"sys6010","nct":"NCT07254585","title":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","primaryCompletion":"2028-06-30","kind":"primary-completion","from":"2026-06-30","to":"2028-06-30"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07267338","title":"Pembrolizumab + MRGOO3 as Neoadjuvant in NPC","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2027-10","kind":"status","from":"NOT_YET_RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07267338","title":"Pembrolizumab + MRGOO3 as Neoadjuvant in NPC","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2027-10","kind":"primary-completion","from":"2027-12","to":"2027-10"},{"detected":"2026-10-26","drugId":"fludeoxyglucose-f18","nct":"NCT07293247","title":"A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment","phases":["PHASE2"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2032-12-31","kind":"primary-completion","from":"2028-12-31","to":"2032-12-31"},{"detected":"2026-10-26","drugId":"duvelisib","nct":"NCT07293403","title":"Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2028-09-17","kind":"primary-completion","from":"2027-11-23","to":"2028-09-17"},{"detected":"2026-10-26","drugId":"blinatumomab","nct":"NCT07297914","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","phases":["PHASE2","PHASE3"],"sponsor":"Bambino Gesù Hospital and Research Institute","primaryCompletion":"2032-11-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07331428","title":"MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC","phases":["PHASE2"],"sponsor":"Fujian Cancer Hospital","primaryCompletion":"2027-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"iparomlimab-tuvonralimab","nct":"NCT07416058","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","phases":["PHASE2"],"sponsor":"Guangdong Association of Clinical Trials","primaryCompletion":"2027-12-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"iparomlimab-tuvonralimab","nct":"NCT07416058","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","phases":["PHASE2"],"sponsor":"Guangdong Association of Clinical Trials","primaryCompletion":"2027-12-30","kind":"primary-completion","from":"2027-12-31","to":"2027-12-30"},{"detected":"2026-10-26","drugId":"trastuzumab-deruxtecan","nct":"NCT07428044","title":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-02-13","kind":"status","from":"RECRUITING","to":"WITHDRAWN"},{"detected":"2026-10-26","drugId":"garsorasib","nct":"NCT07472478","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","phases":["PHASE2"],"sponsor":"Guangdong Provincial People's Hospital","primaryCompletion":"2027-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"folfoxiri","nct":"NCT07472868","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","phases":["PHASE3"],"sponsor":"J. W. A. Burger","primaryCompletion":"2030-03-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"pimicotinib","nct":"NCT07499362","title":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","phases":["PHASE2"],"sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","primaryCompletion":"2028-08-22","kind":"primary-completion","from":"2029-11-22","to":"2028-08-22"},{"detected":"2026-10-26","drugId":"nirogacestat","nct":"NCT07539454","title":"Nirogacestat in Patients With Kaposi Sarcoma","phases":["PHASE2"],"sponsor":"AIDS Malignancy Consortium","primaryCompletion":"2030-02-17","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"alpelisib","nct":"NCT07543822","title":"24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs","phases":["PHASE2"],"sponsor":"Children's Hospital of Philadelphia","primaryCompletion":"2029-10-27","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"alpelisib","nct":"NCT07543822","title":"24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs","phases":["PHASE2"],"sponsor":"Children's Hospital of Philadelphia","primaryCompletion":"2029-10-27","kind":"primary-completion","from":"2029-08-27","to":"2029-10-27"},{"detected":"2026-10-26","drugId":"golcadomide","nct":"NCT07578077","title":"Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2030-04-21","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"balstilimab","nct":"NCT07595874","title":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2028-12-16","kind":"primary-completion","from":"2027-05-27","to":"2028-12-16"},{"detected":"2026-10-26","drugId":"ravulizumab","nct":"NCT07596784","title":"Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)","phases":["PHASE3"],"sponsor":"Alexion Pharmaceuticals, Inc.","primaryCompletion":"2027-08-24","kind":"primary-completion","from":"2027-08-17","to":"2027-08-24"},{"detected":"2026-10-26","drugId":"serplulimab","nct":"NCT07621484","title":"HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer","phases":["PHASE2"],"sponsor":"Shanghai Changzheng Hospital","primaryCompletion":"2028-05-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"trastuzumab-rezetecan","nct":"NCT07624201","title":"Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer","phases":["PHASE2"],"sponsor":"Harbin Medical University","primaryCompletion":"2028-06-01","kind":"status","from":"NOT_YET_RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"bexmarilimab","nct":"NCT07672769","title":"Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes","phases":["PHASE2"],"sponsor":"Faron Pharmaceuticals Ltd","primaryCompletion":"2027-11","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"bexmarilimab","nct":"NCT07672769","title":"Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes","phases":["PHASE2"],"sponsor":"Faron Pharmaceuticals Ltd","primaryCompletion":"2027-11","kind":"primary-completion","from":"2027-11-30","to":"2027-11"},{"detected":"2026-10-26","drugId":"safusidenib","nct":"NCT07703436","title":"Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease","phases":["PHASE2"],"sponsor":"Nuvation Bio Inc.","primaryCompletion":"2030-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"glofitamab","nct":"NCT07711483","title":"GLORY: Glofit-GemOx With Liso-Cel For Lymphoma","phases":["PHASE2"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2028-09-15","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"glofitamab","nct":"NCT07711483","title":"GLORY: Glofit-GemOx With Liso-Cel For Lymphoma","phases":["PHASE2"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2028-09-15","kind":"primary-completion","from":"2028-10-01","to":"2028-09-15"},{"detected":"2026-10-26","drugId":"qls31905","nct":"NCT07716449","title":"QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ","phases":["PHASE3"],"sponsor":"Qilu Pharmaceutical Co., Ltd.","primaryCompletion":"2028-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"azd0120","nct":"NCT07735637","title":"A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-11-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"azd0120","nct":"NCT07735637","title":"A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-11-02","kind":"primary-completion","from":"2028-10-11","to":"2028-11-02"},{"detected":"2026-10-26","drugId":"inavolisib","nct":"NCT07748208","title":"A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2029-06-15","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"hpv-bivalent-vaccine","nct":"NCT07785843","title":"A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2027-12-18","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"hs-20093","nct":"NCT07824882","title":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","phases":["PHASE2"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2028-03-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"trilaciclib","nct":"NCT07881705","title":"A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","primaryCompletion":"2027-07-15","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"benmelstobart","nct":"NCT07881900","title":"Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma","phases":["PHASE3"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2027-06-30","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-26","drugId":"epcoritamab","nct":"NCT07882173","title":"Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)","phases":["PHASE2"],"sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","primaryCompletion":"2030-11-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07882940","title":"Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC","phases":["PHASE2"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2029-10-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"netupitant-palonosetron","nct":"NCT07882966","title":"Prophylaxis for Emetogenic radioTherapy With Akynzeo","phases":["PHASE2"],"sponsor":"University Health Network, Toronto","primaryCompletion":"2028-11-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"epcoritamab","nct":"NCT07883135","title":"Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas","phases":["PHASE2"],"sponsor":"National Research Center for Hematology, Russia","primaryCompletion":"2028-10-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"gecacitinib","nct":"NCT07883382","title":"An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation","phases":["PHASE1","PHASE2"],"sponsor":"Ruijin Hospital","primaryCompletion":"2028-10-15","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07884188","title":"Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2028-10-15","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"danazol","nct":"NCT07884773","title":"Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia","phases":["PHASE3"],"sponsor":"Khyber Medical University Peshawar","primaryCompletion":"2027-04-12","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"flumatinib","nct":"NCT07885293","title":"A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","phases":["PHASE3"],"sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","primaryCompletion":"2029-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"sonrotoclax","nct":"NCT07885397","title":"Sonrotoclax Plus Azacitidine in Patients With MDS-IB2","phases":["PHASE1","PHASE2"],"sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","primaryCompletion":"2027-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"bgb-16673","nct":"NCT07887061","title":"Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","phases":["PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2031-07-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"anitocabtagene-autoleucel","nct":"NCT07887672","title":"A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma","phases":["PHASE3"],"sponsor":"Kite, A Gilead Company","primaryCompletion":"2042-02","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"odronextamab","nct":"NCT07887750","title":"REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)","phases":["PHASE1","PHASE2"],"sponsor":"Regeneron Pharmaceuticals","primaryCompletion":"2029-11-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"talquetamab","nct":"NCT07887984","title":"Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma","phases":["PHASE2","PHASE3"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2033-08-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"glofitamab","nct":"NCT07888621","title":"Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital with Nanjing Medical University","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"imiquimod","nct":"NCT07888647","title":"IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas","phases":["PHASE2"],"sponsor":"German Cancer Research Center","primaryCompletion":"2034-02-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"megestrol-progestins","nct":"NCT07890064","title":"Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer","phases":["PHASE2"],"sponsor":"Wang Yingmei","primaryCompletion":"2029-01-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07890311","title":"Single-arm, Multicenter, Open-label Phase II Study of Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer","phases":["PHASE2"],"sponsor":"Jiangmen Central Hospital","primaryCompletion":"2027-09-22","kind":"new-study","to":"ENROLLING_BY_INVITATION"},{"detected":"2026-10-26","drugId":"benmelstobart","nct":"NCT07890506","title":"Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC","phases":["PHASE2"],"sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"atirmociclib","nct":"NCT07890597","title":"A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer","phases":["PHASE3"],"sponsor":"Pfizer","primaryCompletion":"2032-04-13","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"datopotamab-deruxtecan","nct":"NCT07890714","title":"A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]","phases":["PHASE1","PHASE2"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2029-09-30","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"mirdametinib","nct":"NCT07891286","title":"Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-01-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"fluoxymesterone","nct":"NCT07891338","title":"Exploratory Study of the Efficacy of HAL-PDT in CIN 3","phases":["PHASE2"],"sponsor":"Tongji Hospital","primaryCompletion":"2028-06","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"axicabtagene-ciloleucel","nct":"NCT07892027","title":"Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy","phases":["PHASE2"],"sponsor":"University of Michigan Rogel Cancer Center","primaryCompletion":"2028-05-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"dalpiciclib","nct":"NCT07892274","title":"Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer","phases":["PHASE3"],"sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","primaryCompletion":"2030-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-26","drugId":"mrg003","nct":"NCT07892833","title":"Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital of Bengbu Medical University","primaryCompletion":"2028-05-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-26","drugId":"ceritinib","nct":"NCT07893197","title":"Ceritinib Treatment for Recurrent Meningiomas","phases":["PHASE2"],"sponsor":"Kevin Petrecca","primaryCompletion":"2031-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"abemaciclib","nct":"NCT02747004","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2018-06-15","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"neratinib","nct":"NCT03377387","title":"Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-10-14","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"neratinib","nct":"NCT03377387","title":"Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-10-14","kind":"primary-completion","from":"2026-12","to":"2026-10-14"},{"detected":"2026-10-19","drugId":"anetumab-ravtansine","nct":"NCT03587311","title":"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-12-15","kind":"primary-completion","from":"2026-10-21","to":"2027-12-15"},{"detected":"2026-10-19","drugId":"degarelix","nct":"NCT03689699","title":"Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)","phases":["PHASE1","PHASE2"],"sponsor":"Mark Stein","primaryCompletion":"2023-09-22","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"zolbetuximab","nct":"NCT03816163","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","phases":["PHASE2"],"sponsor":"Astellas Pharma Global Development, Inc.","primaryCompletion":"2026-10-31","kind":"primary-completion","from":"2026-08-31","to":"2026-10-31"},{"detected":"2026-10-19","drugId":"ponatinib","nct":"NCT04233346","title":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","phases":["PHASE2"],"sponsor":"Otsuka Beijing Research Institute","primaryCompletion":"2022-07-22","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"lurbinectedin","nct":"NCT04607954","title":"Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2026-03-02","kind":"primary-completion","from":"2026-09-01","to":"2026-03-02"},{"detected":"2026-10-19","drugId":"avelumab","nct":"NCT04841148","title":"Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2027-07","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"belantamab-mafodotin","nct":"NCT04876248","title":"Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant","phases":["PHASE2"],"sponsor":"Roswell Park Cancer Institute","primaryCompletion":"2026-07-29","kind":"primary-completion","from":"2027-07-29","to":"2026-07-29"},{"detected":"2026-10-19","drugId":"obinutuzumab","nct":"NCT04920968","title":"Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 \"OVERALL\"","phases":["PHASE2"],"sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","primaryCompletion":"2026-04-21","kind":"status","from":"RECRUITING","to":"TERMINATED"},{"detected":"2026-10-19","drugId":"obinutuzumab","nct":"NCT04920968","title":"Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 \"OVERALL\"","phases":["PHASE2"],"sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","primaryCompletion":"2026-04-21","kind":"primary-completion","from":"2025-12-31","to":"2026-04-21"},{"detected":"2026-10-19","drugId":"alpelisib","nct":"NCT04980833","title":"Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2027-06-22","kind":"primary-completion","from":"2027-08-20","to":"2027-06-22"},{"detected":"2026-10-19","drugId":"alpelisib","nct":"NCT05063786","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)","phases":["PHASE3"],"sponsor":"Spanish Breast Cancer Research Group","primaryCompletion":"2025-12-23","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-19","drugId":"alpelisib","nct":"NCT05063786","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)","phases":["PHASE3"],"sponsor":"Spanish Breast Cancer Research Group","primaryCompletion":"2025-12-23","kind":"primary-completion","from":"2026-06","to":"2025-12-23"},{"detected":"2026-10-19","drugId":"enfortumab-vedotin","nct":"NCT05239624","title":"Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"cemiplimab","nct":"NCT05317858","title":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","phases":["PHASE3"],"sponsor":"InSightec","primaryCompletion":"2031-06-01","kind":"primary-completion","from":"2027-06-01","to":"2031-06-01"},{"detected":"2026-10-19","drugId":"dalpiciclib","nct":"NCT05328440","title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2028-01-01","kind":"status","from":"UNKNOWN","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"dalpiciclib","nct":"NCT05328440","title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2028-01-01","kind":"primary-completion","from":"2024-06-01","to":"2028-01-01"},{"detected":"2026-10-19","drugId":"relatlimab-nivolumab","nct":"NCT05337137","title":"A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2025-07-05","kind":"results-posted"},{"detected":"2026-10-19","drugId":"neratinib","nct":"NCT05388149","title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","phases":["PHASE2"],"sponsor":"University Health Network, Toronto","primaryCompletion":"2027-07","kind":"primary-completion","from":"2026-07","to":"2027-07"},{"detected":"2026-10-19","drugId":"iberdomide","nct":"NCT05392946","title":"Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study","phases":["PHASE1","PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2026-09-18","kind":"primary-completion","from":"2026-09-29","to":"2026-09-18"},{"detected":"2026-10-19","drugId":"ivermectin","nct":"NCT05500326","title":"Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)","phases":["PHASE2"],"sponsor":"Murdoch Childrens Research Institute","primaryCompletion":"2026-12","kind":"primary-completion","from":"2026-06","to":"2026-12"},{"detected":"2026-10-19","drugId":"brigimadlin","nct":"NCT05512377","title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","phases":["PHASE2"],"sponsor":"Boehringer Ingelheim","primaryCompletion":"2025-09-25","kind":"results-posted"},{"detected":"2026-10-19","drugId":"blinatumomab","nct":"NCT05519579","title":"Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","phases":["PHASE2"],"sponsor":"Northside Hospital, Inc.","primaryCompletion":"2027-02-01","kind":"primary-completion","from":"2026-11-01","to":"2027-02-01"},{"detected":"2026-10-19","drugId":"diazoxide","nct":"NCT05532020","title":"An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities","phases":["PHASE2"],"sponsor":"Soleno Therapeutics, Inc.","primaryCompletion":"2024-01","kind":"status","from":"UNKNOWN","to":"WITHDRAWN"},{"detected":"2026-10-19","drugId":"selumetinib","nct":"NCT05554328","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-09-23","kind":"primary-completion","from":"2028-10-01","to":"2026-09-23"},{"detected":"2026-10-19","drugId":"alpelisib","nct":"NCT05625087","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","phases":["PHASE2"],"sponsor":"UNICANCER","primaryCompletion":"2025-03-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-10-19","drugId":"alpelisib","nct":"NCT05625087","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","phases":["PHASE2"],"sponsor":"UNICANCER","primaryCompletion":"2025-03-30","kind":"primary-completion","from":"2028-07","to":"2025-03-30"},{"detected":"2026-10-19","drugId":"datopotamab-deruxtecan","nct":"NCT05629585","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2027-09-20","to":"2027-09-01"},{"detected":"2026-10-19","drugId":"cpx-351","nct":"NCT05656248","title":"Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms","phases":["PHASE2"],"sponsor":"St. Jude Children's Research Hospital","primaryCompletion":"2025-08-28","kind":"results-posted"},{"detected":"2026-10-19","drugId":"lisocabtagene-maraleucel","nct":"NCT05664217","title":"NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma","phases":["PHASE2","PHASE3"],"sponsor":"Nektar Therapeutics","primaryCompletion":"2024-05-22","kind":"results-posted"},{"detected":"2026-10-19","drugId":"itm-11","nct":"NCT05691465","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-06-01","kind":"primary-completion","from":"2026-11-02","to":"2027-06-01"},{"detected":"2026-10-19","drugId":"diazoxide","nct":"NCT05701774","title":"Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome","phases":["PHASE3"],"sponsor":"Soleno Therapeutics, Inc.","primaryCompletion":"2026-01-12","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"diazoxide","nct":"NCT05701774","title":"Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome","phases":["PHASE3"],"sponsor":"Soleno Therapeutics, Inc.","primaryCompletion":"2026-01-12","kind":"primary-completion","from":"2028-06","to":"2026-01-12"},{"detected":"2026-10-19","drugId":"tiragolumab","nct":"NCT05715281","title":"Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2025-10-06","kind":"results-posted"},{"detected":"2026-10-19","drugId":"ropeginterferon-alfa-2b","nct":"NCT05731245","title":"Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis","phases":["PHASE2"],"sponsor":"National Taiwan University Hospital","primaryCompletion":"2024-10-12","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-19","drugId":"golcadomide","nct":"NCT05788081","title":"Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.","phases":["PHASE2"],"sponsor":"Olivia Newton-John Cancer Research Institute","primaryCompletion":"2028-01-01","kind":"primary-completion","from":"2027-01-01","to":"2028-01-01"},{"detected":"2026-10-19","drugId":"erdafitinib","nct":"NCT05859334","title":"Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-10-23","kind":"primary-completion","from":"2026-10-23","to":"2027-10-23"},{"detected":"2026-10-19","drugId":"human-normal-immunoglobulin","nct":"NCT05886036","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-10-31","kind":"primary-completion","from":"2026-10-31","to":"2028-10-31"},{"detected":"2026-10-19","drugId":"polatuzumab-vedotin","nct":"NCT05940064","title":"Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma","phases":["PHASE2"],"sponsor":"Peng Liu","primaryCompletion":"2026-01-15","kind":"status","from":"UNKNOWN","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"polatuzumab-vedotin","nct":"NCT05940064","title":"Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma","phases":["PHASE2"],"sponsor":"Peng Liu","primaryCompletion":"2026-01-15","kind":"primary-completion","from":"2025-07-20","to":"2026-01-15"},{"detected":"2026-10-19","drugId":"belumosudil","nct":"NCT06046248","title":"Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","phases":["PHASE2"],"sponsor":"Northside Hospital, Inc.","primaryCompletion":"2027-03-31","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-10-19","drugId":"belumosudil","nct":"NCT06046248","title":"Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","phases":["PHASE2"],"sponsor":"Northside Hospital, Inc.","primaryCompletion":"2027-03-31","kind":"primary-completion","from":"2026-12-31","to":"2027-03-31"},{"detected":"2026-10-19","drugId":"belinostat","nct":"NCT06072131","title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","phases":["PHASE3"],"sponsor":"Acrotech Biopharma Inc.","primaryCompletion":"2030-07","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"dronabinol","nct":"NCT06097533","title":"Improvement of Quality of Life by Cannabinoids in Oncologic Patients","phases":["PHASE2"],"sponsor":"University Hospital Schleswig-Holstein","primaryCompletion":"2026-02-05","kind":"status","from":"RECRUITING","to":"TERMINATED"},{"detected":"2026-10-19","drugId":"dronabinol","nct":"NCT06097533","title":"Improvement of Quality of Life by Cannabinoids in Oncologic Patients","phases":["PHASE2"],"sponsor":"University Hospital Schleswig-Holstein","primaryCompletion":"2026-02-05","kind":"primary-completion","from":"2026-11-30","to":"2026-02-05"},{"detected":"2026-10-19","drugId":"azd0486","nct":"NCT06137118","title":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2028-01-06","kind":"primary-completion","from":"2028-02-11","to":"2028-01-06"},{"detected":"2026-10-19","drugId":"mhb036c","nct":"NCT06373406","title":"A Study of MHB036C for Advanced Solid Tumor","phases":["PHASE1","PHASE2"],"sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","primaryCompletion":"2027-04","kind":"primary-completion","from":"2025-12","to":"2027-04"},{"detected":"2026-10-19","drugId":"datopotamab-deruxtecan","nct":"NCT06417814","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2027-01-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"datopotamab-deruxtecan","nct":"NCT06417814","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2027-01-11","kind":"primary-completion","from":"2026-09-30","to":"2027-01-11"},{"detected":"2026-10-19","drugId":"yl202","nct":"NCT06439771","title":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","phases":["PHASE2"],"sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","primaryCompletion":"2027-07-30","kind":"primary-completion","from":"2026-07-30","to":"2027-07-30"},{"detected":"2026-10-19","drugId":"utidelone","nct":"NCT06458413","title":"Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"Min Yan, MD","primaryCompletion":"2026-07-09","kind":"status","from":"UNKNOWN","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"utidelone","nct":"NCT06458413","title":"Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"Min Yan, MD","primaryCompletion":"2026-07-09","kind":"primary-completion","from":"2025-06-05","to":"2026-07-09"},{"detected":"2026-10-19","drugId":"hs-20093","nct":"NCT06498479","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2026-08-20","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"hs-20093","nct":"NCT06498479","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2026-08-20","kind":"primary-completion","from":"2026-09-30","to":"2026-08-20"},{"detected":"2026-10-19","drugId":"ivosidenib","nct":"NCT06501625","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","phases":["PHASE1","PHASE2"],"sponsor":"Institut de Recherches Internationales Servier","primaryCompletion":"2027-09-13","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"ivosidenib","nct":"NCT06501625","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","phases":["PHASE1","PHASE2"],"sponsor":"Institut de Recherches Internationales Servier","primaryCompletion":"2027-09-13","kind":"primary-completion","from":"2026-07-23","to":"2027-09-13"},{"detected":"2026-10-19","drugId":"ak117","nct":"NCT06508606","title":"AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2026-08-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"ak117","nct":"NCT06508606","title":"AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2026-08-01","kind":"primary-completion","from":"2026-11-01","to":"2026-08-01"},{"detected":"2026-10-19","drugId":"utidelone","nct":"NCT06598046","title":"A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2028-06-01","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"utidelone","nct":"NCT06598046","title":"A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2028-06-01","kind":"primary-completion","from":"2026-06-01","to":"2028-06-01"},{"detected":"2026-10-19","drugId":"atigotatug","nct":"NCT06646276","title":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","phases":["PHASE3"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2027-08-17","kind":"primary-completion","from":"2028-04-06","to":"2027-08-17"},{"detected":"2026-10-19","drugId":"arx788","nct":"NCT06663748","title":"ARX788 in HER2-positive Metastatic Breast Cancer Patients","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2027-11-20","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"arx788","nct":"NCT06663748","title":"ARX788 in HER2-positive Metastatic Breast Cancer Patients","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2027-11-20","kind":"primary-completion","from":"2025-11-20","to":"2027-11-20"},{"detected":"2026-10-19","drugId":"luveltamab-tazevibulin","nct":"NCT06679582","title":"Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML","phases":["PHASE1","PHASE2"],"sponsor":"Sutro Biopharma, Inc.","primaryCompletion":"2025-01-21","kind":"results-posted"},{"detected":"2026-10-19","drugId":"luveltamab-tazevibulin","nct":"NCT06679582","title":"Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML","phases":["PHASE1","PHASE2"],"sponsor":"Sutro Biopharma, Inc.","primaryCompletion":"2025-01-21","kind":"primary-completion","from":"2025-06-01","to":"2025-01-21"},{"detected":"2026-10-19","drugId":"pm8002","nct":"NCT06712355","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","phases":["PHASE3"],"sponsor":"BioNTech SE","primaryCompletion":"2029-04","kind":"primary-completion","from":"2028-12","to":"2029-04"},{"detected":"2026-10-19","drugId":"cadonilimab","nct":"NCT06762080","title":"Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","phases":["PHASE1","PHASE2"],"sponsor":"Guangzhou Medical University","primaryCompletion":"2026-10-30","kind":"primary-completion","from":"2026-09-30","to":"2026-10-30"},{"detected":"2026-10-19","drugId":"capivasertib","nct":"NCT06764186","title":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2027-11-30","kind":"primary-completion","from":"2027-12-31","to":"2027-11-30"},{"detected":"2026-10-19","drugId":"pacritinib","nct":"NCT06782373","title":"A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","phases":["PHASE2"],"sponsor":"Swedish Orphan Biovitrum","primaryCompletion":"2026-12-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"memantine","nct":"NCT06789757","title":"The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)","phases":["PHASE2"],"sponsor":"Inova Health Care Services","primaryCompletion":"2028-10-27","kind":"primary-completion","from":"2026-10-27","to":"2028-10-27"},{"detected":"2026-10-19","drugId":"cemiplimab","nct":"NCT06923761","title":"EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)","phases":["PHASE1","PHASE2"],"sponsor":"Grey Wolf Therapeutics","primaryCompletion":"2027-04-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"hs-20093","nct":"NCT06935409","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2026-06-17","kind":"primary-completion","from":"2026-08-31","to":"2026-06-17"},{"detected":"2026-10-19","drugId":"romiplostim","nct":"NCT07001254","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","phases":["PHASE2"],"sponsor":"Anjali Sharathkumar","primaryCompletion":"2031-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-10-19","drugId":"glofitamab","nct":"NCT07012980","title":"Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL","phases":["PHASE2"],"sponsor":"Shanghai Zhongshan Hospital","primaryCompletion":"2027-03-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"glofitamab","nct":"NCT07012980","title":"Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL","phases":["PHASE2"],"sponsor":"Shanghai Zhongshan Hospital","primaryCompletion":"2027-03-31","kind":"primary-completion","from":"2026-07-31","to":"2027-03-31"},{"detected":"2026-10-19","drugId":"paltusotine","nct":"NCT07087054","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","phases":["PHASE3"],"sponsor":"Crinetics Pharmaceuticals Inc.","primaryCompletion":"2027-08","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"azd4512","nct":"NCT07109219","title":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2028-10-11","kind":"primary-completion","from":"2028-04-28","to":"2028-10-11"},{"detected":"2026-10-19","drugId":"hrs-8080","nct":"NCT07125950","title":"SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2027-09-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"zipalertinib","nct":"NCT07128199","title":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","phases":["PHASE3"],"sponsor":"Taiho Oncology, Inc.","primaryCompletion":"2029-10-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"nalirifox","nct":"NCT07173387","title":"Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer","phases":["PHASE2"],"sponsor":"Shandong Cancer Hospital and Institute","primaryCompletion":"2028-10-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"yl202","nct":"NCT07202364","title":"A Study of YL202 in Patients With Advanced Solid Tumors","phases":["PHASE2"],"sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","primaryCompletion":"2027-01-31","kind":"primary-completion","from":"2026-08-31","to":"2027-01-31"},{"detected":"2026-10-19","drugId":"pirtobrutinib","nct":"NCT07220187","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","phases":["PHASE3"],"sponsor":"SWOG Cancer Research Network","primaryCompletion":"2035-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"pf-08634404","nct":"NCT07392892","title":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","phases":["PHASE2","PHASE3"],"sponsor":"Pfizer","primaryCompletion":"2031-07-22","kind":"primary-completion","from":"2032-01-15","to":"2031-07-22"},{"detected":"2026-10-19","drugId":"dinutuximab","nct":"NCT07437963","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-09-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"nemtabrutinib","nct":"NCT07557056","title":"Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phases":["PHASE2"],"sponsor":"Jennifer Woyach","primaryCompletion":"2027-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"lorigerlimab","nct":"NCT07565155","title":"Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency","phases":["PHASE2"],"sponsor":"University of Miami","primaryCompletion":"2032-01-01","kind":"primary-completion","from":"2031-06-01","to":"2032-01-01"},{"detected":"2026-10-19","drugId":"relatlimab-nivolumab","nct":"NCT07574047","title":"MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.","phases":["PHASE2"],"sponsor":"Swiss Cancer Institute","primaryCompletion":"2030-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"hlx11","nct":"NCT07578116","title":"Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis","phases":["PHASE3"],"sponsor":"SWOG Cancer Research Network","primaryCompletion":"2032-05-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"bendamustine","nct":"NCT07593482","title":"Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.","phases":["PHASE2"],"sponsor":"Swiss Cancer Institute","primaryCompletion":"2029-03","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"ropeginterferon-alfa-2b","nct":"NCT07646821","title":"A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-11","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"dostarlimab","nct":"NCT07684599","title":"A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)","phases":["PHASE3"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-07-23","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"darolutamide","nct":"NCT07711002","title":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2031-05-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"darolutamide","nct":"NCT07711002","title":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2031-05-30","kind":"primary-completion","from":"2031-06-17","to":"2031-05-30"},{"detected":"2026-10-19","drugId":"tafasitamab","nct":"NCT07731789","title":"Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2030-10-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"raludotatug-deruxtecan","nct":"NCT07743164","title":"A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2031-08-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"ssgj-612","nct":"NCT07757230","title":"A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","primaryCompletion":"2028-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"abemaciclib","nct":"NCT07767474","title":"A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Antares Therapeutics, Inc","primaryCompletion":"2029-10-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"abemaciclib","nct":"NCT07767474","title":"A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Antares Therapeutics, Inc","primaryCompletion":"2029-10-28","kind":"primary-completion","from":"2028-10-28","to":"2029-10-28"},{"detected":"2026-10-19","drugId":"megestrol","nct":"NCT07796789","title":"Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma","phases":["PHASE3"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2027-09-29","kind":"primary-completion","from":"2027-08-30","to":"2027-09-29"},{"detected":"2026-10-19","drugId":"azd5335","nct":"NCT07816666","title":"Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-09-29","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"azd5335","nct":"NCT07816666","title":"Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-09-29","kind":"primary-completion","from":"2028-09-26","to":"2028-09-29"},{"detected":"2026-10-19","drugId":"obrixtamig","nct":"NCT07843940","title":"A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)","phases":["PHASE1","PHASE2"],"sponsor":"Boehringer Ingelheim","primaryCompletion":"2030-04-17","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"trastuzumab-brengitecan","nct":"NCT07869836","title":"BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy","phases":["PHASE3"],"sponsor":"SystImmune Inc.","primaryCompletion":"2028-12","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"darolutamide","nct":"NCT07871110","title":"Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)","phases":["PHASE2"],"sponsor":"TransThera Sciences (Nanjing), Inc.","primaryCompletion":"2028-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"pasritamig","nct":"NCT07871435","title":"GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)","phases":["PHASE1","PHASE2"],"sponsor":"GI Innovation, Inc.","primaryCompletion":"2029-03-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"flot","nct":"NCT07872722","title":"Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","phases":["PHASE2"],"sponsor":"National Cancer Center, Japan","primaryCompletion":"2030-03-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"rc148","nct":"NCT07874282","title":"Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer","phases":["PHASE2"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2027-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"mrg003","nct":"NCT07874321","title":"MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer","phases":["PHASE2"],"sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","primaryCompletion":"2027-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-19","drugId":"retlirafusp-alfa","nct":"NCT07874425","title":"Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"sotorasib","nct":"NCT07874737","title":"Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia","phases":["PHASE2"],"sponsor":"The Affiliated People's Hospital of Ningbo University","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"ssgj-706","nct":"NCT07874984","title":"SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","primaryCompletion":"2027-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"eflornithine","nct":"NCT07876323","title":"Randomized Split-Face Controlled Study to Evaluate the Effectiveness of Topical Eflornithine 9.58% + Hydroquinone 4% + Fluocinolone 0.01% as Compared to Topical Tretinoin 0.05% + Hydroquinone 4% + Fluocinolone 0.01% for the Treatment of Melasma","phases":["PHASE2"],"sponsor":"National Skin Centre","primaryCompletion":"2024-07-11","kind":"new-study","to":"COMPLETED"},{"detected":"2026-10-19","drugId":"inca33890","nct":"NCT07876414","title":"A Clinical Trial Comparing an Antibody (INCA33890) Versus Pembrolizumab for Squamous Cell Carcinoma of the Head and Neck.","phases":["PHASE2"],"sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","primaryCompletion":"2030-02","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"flot","nct":"NCT07877818","title":"A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2029-11-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"zanzalintinib","nct":"NCT07878689","title":"Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"University of Texas Southwestern Medical Center","primaryCompletion":"2028-12-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"nelarabine","nct":"NCT00501826","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-10-31","kind":"primary-completion","from":"2026-10-31","to":"2028-10-31"},{"detected":"2026-10-12","drugId":"fedratinib","nct":"NCT00724334","title":"A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis","phases":["PHASE1","PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2014-05-28","kind":"results-posted"},{"detected":"2026-10-12","drugId":"fedratinib","nct":"NCT00724334","title":"A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis","phases":["PHASE1","PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2014-05-28","kind":"primary-completion","from":"2014-05","to":"2014-05-28"},{"detected":"2026-10-12","drugId":"fludeoxyglucose-f18","nct":"NCT01542879","title":"Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Stanford University","primaryCompletion":"2022-08-08","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"fludeoxyglucose-f18","nct":"NCT01542879","title":"Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Stanford University","primaryCompletion":"2022-08-08","kind":"results-posted"},{"detected":"2026-10-12","drugId":"fludeoxyglucose-f18","nct":"NCT01542879","title":"Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Stanford University","primaryCompletion":"2022-08-08","kind":"primary-completion","from":"2025-10","to":"2022-08-08"},{"detected":"2026-10-12","drugId":"ziv-aflibercept","nct":"NCT02157077","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","phases":["PHASE3"],"sponsor":"Centre Hospitalier Intercommunal Creteil","primaryCompletion":"2015-12","kind":"results-posted"},{"detected":"2026-10-12","drugId":"lutathera","nct":"NCT02236910","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2027-12","kind":"status","from":"UNKNOWN","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"lutathera","nct":"NCT02236910","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2027-12","kind":"primary-completion","from":"2025-12","to":"2027-12"},{"detected":"2026-10-12","drugId":"fludeoxyglucose-f18","nct":"NCT02824419","title":"Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis","phases":["PHASE2","PHASE3"],"sponsor":"Turku University Hospital","primaryCompletion":"2017-02","kind":"status","from":"UNKNOWN","to":"TERMINATED"},{"detected":"2026-10-12","drugId":"fludeoxyglucose-f18","nct":"NCT02824419","title":"Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis","phases":["PHASE2","PHASE3"],"sponsor":"Turku University Hospital","primaryCompletion":"2017-02","kind":"primary-completion","from":"2017-05","to":"2017-02"},{"detected":"2026-10-12","drugId":"alectinib","nct":"NCT03194893","title":"A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-09-18","kind":"results-posted"},{"detected":"2026-10-12","drugId":"ensartinib","nct":"NCT03213652","title":"Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2025-09-30","kind":"results-posted"},{"detected":"2026-10-12","drugId":"emavusertib","nct":"NCT03328078","title":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","phases":["PHASE1","PHASE2"],"sponsor":"Curis, Inc.","primaryCompletion":"2027-07","kind":"primary-completion","from":"2026-08","to":"2027-07"},{"detected":"2026-10-12","drugId":"trastuzumab-deruxtecan","nct":"NCT03529110","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","phases":["PHASE3"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2021-05-21","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"relatlimab-nivolumab","nct":"NCT03607890","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","phases":["PHASE2"],"sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","primaryCompletion":"2027-10","kind":"primary-completion","from":"2026-10","to":"2027-10"},{"detected":"2026-10-12","drugId":"oleclumab","nct":"NCT03616886","title":"Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC","phases":["PHASE1","PHASE2"],"sponsor":"Jules Bordet Institute","primaryCompletion":"2021-05-21","kind":"primary-completion","from":"2025-03","to":"2021-05-21"},{"detected":"2026-10-12","drugId":"abiraterone","nct":"NCT03678025","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","phases":["PHASE3"],"sponsor":"SWOG Cancer Research Network","primaryCompletion":"2033-04-01","kind":"primary-completion","from":"2028-04-01","to":"2033-04-01"},{"detected":"2026-10-12","drugId":"palbociclib","nct":"NCT03709680","title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","phases":["PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2024-08-26","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"palbociclib","nct":"NCT03709680","title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","phases":["PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2024-08-26","kind":"results-posted"},{"detected":"2026-10-12","drugId":"apalutamide","nct":"NCT03821792","title":"Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-10-11","kind":"primary-completion","from":"2026-10-11","to":"2028-10-11"},{"detected":"2026-10-12","drugId":"oleclumab","nct":"NCT03875573","title":"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:","phases":["PHASE2"],"sponsor":"Jules Bordet Institute","primaryCompletion":"2024-11-30","kind":"primary-completion","from":"2025-05-30","to":"2024-11-30"},{"detected":"2026-10-12","drugId":"daratumumab","nct":"NCT04052880","title":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","phases":["PHASE2"],"sponsor":"Larysa Sanchez","primaryCompletion":"2025-05-20","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"denosumab","nct":"NCT04067726","title":"RANKL Inhibition and Mammographic Breast Density","phases":["PHASE2"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2025-09-17","kind":"results-posted"},{"detected":"2026-10-12","drugId":"radium-223","nct":"NCT04071236","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-04-30","kind":"status","from":"SUSPENDED","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"ifinatamab-deruxtecan","nct":"NCT04145622","title":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2027-04-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"sacituzumab-tirumotecan","nct":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phases":["PHASE1","PHASE2"],"sponsor":"Klus Pharma Inc.","primaryCompletion":"2025-11-30","kind":"primary-completion","from":"2026-12-31","to":"2025-11-30"},{"detected":"2026-10-12","drugId":"ponatinib","nct":"NCT04160546","title":"Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)","phases":["PHASE2"],"sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","primaryCompletion":"2025-12-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"ponatinib","nct":"NCT04160546","title":"Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)","phases":["PHASE2"],"sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","primaryCompletion":"2025-12-31","kind":"primary-completion","from":"2025-12","to":"2025-12-31"},{"detected":"2026-10-12","drugId":"talazoparib","nct":"NCT04337970","title":"Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2025-05-23","kind":"results-posted"},{"detected":"2026-10-12","drugId":"acalabrutinib","nct":"NCT04404088","title":"Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-03-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"adavosertib","nct":"NCT04439227","title":"Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2020-05-29","kind":"results-posted"},{"detected":"2026-10-12","drugId":"olaparib","nct":"NCT04548752","title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2025-07-16","kind":"primary-completion","from":"2026-10-01","to":"2025-07-16"},{"detected":"2026-10-12","drugId":"atezolizumab","nct":"NCT04624399","title":"Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer","phases":["PHASE2"],"sponsor":"Queen Mary University of London","primaryCompletion":"2026-05-30","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"dabrafenib","nct":"NCT04675710","title":"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-10-30","kind":"primary-completion","from":"2026-10-30","to":"2028-10-30"},{"detected":"2026-10-12","drugId":"vemurafenib","nct":"NCT04943198","title":"Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis","phases":["PHASE2"],"sponsor":"Anna Raciborska","primaryCompletion":"2027-06-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"vemurafenib","nct":"NCT04943224","title":"Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients","phases":["PHASE2"],"sponsor":"Anna Raciborska","primaryCompletion":"2027-06-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"bgb-16673","nct":"NCT05006716","title":"A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-11","to":"2027-03"},{"detected":"2026-10-12","drugId":"romidepsin","nct":"NCT05180461","title":"Emodepside Phase II Trial for Treatment of Onchocerciasis","phases":["PHASE2"],"sponsor":"Drugs for Neglected Diseases","primaryCompletion":"2026-09-18","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-12","drugId":"acalabrutinib","nct":"NCT05388006","title":"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2026-09-23","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"acalabrutinib","nct":"NCT05388006","title":"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2026-09-23","kind":"primary-completion","from":"2027-02-22","to":"2026-09-23"},{"detected":"2026-10-12","drugId":"dronabinol","nct":"NCT05389930","title":"Cannabis' Impact on Alcohol Consumption","phases":["PHASE2"],"sponsor":"Brown University","primaryCompletion":"2027-08-31","kind":"primary-completion","from":"2027-03-31","to":"2027-08-31"},{"detected":"2026-10-12","drugId":"tiragolumab","nct":"NCT05394337","title":"Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"trk-950","nct":"NCT05423262","title":"A Study of TRK-950 in Patients With Advanced Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Toray Industries, Inc","primaryCompletion":"2028-03-31","kind":"primary-completion","from":"2027-12","to":"2028-03-31"},{"detected":"2026-10-12","drugId":"ryz101","nct":"NCT05477576","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","phases":["PHASE3"],"sponsor":"RayzeBio, Inc.","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"lazertinib","nct":"NCT05477615","title":"Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases","phases":["PHASE2"],"sponsor":"Jin Hyoung Kang","primaryCompletion":"2025-10-10","kind":"status","from":"UNKNOWN","to":"TERMINATED"},{"detected":"2026-10-12","drugId":"lazertinib","nct":"NCT05477615","title":"Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases","phases":["PHASE2"],"sponsor":"Jin Hyoung Kang","primaryCompletion":"2025-10-10","kind":"primary-completion","from":"2023-06","to":"2025-10-10"},{"detected":"2026-10-12","drugId":"quizartinib","nct":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-05-15","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"balstilimab","nct":"NCT05571293","title":"Combination Immunotherapy in Colorectal Cancer","phases":["PHASE2"],"sponsor":"Weill Medical College of Cornell University","primaryCompletion":"2024-11-14","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"vactosertib","nct":"NCT05588648","title":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","phases":["PHASE1","PHASE2"],"sponsor":"MedPacto, Inc.","primaryCompletion":"2027-12","kind":"primary-completion","from":"2025-09","to":"2027-12"},{"detected":"2026-10-12","drugId":"tiragolumab","nct":"NCT05661188","title":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","phases":["PHASE2"],"sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","primaryCompletion":"2026-09-25","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"tiragolumab","nct":"NCT05661188","title":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","phases":["PHASE2"],"sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","primaryCompletion":"2026-09-25","kind":"primary-completion","from":"2027-06","to":"2026-09-25"},{"detected":"2026-10-12","drugId":"cabozantinib","nct":"NCT05663710","title":"Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2027-10-30","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-10-12","drugId":"zynlonta","nct":"NCT05672251","title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2029-08-24","kind":"primary-completion","from":"2027-03-23","to":"2029-08-24"},{"detected":"2026-10-12","drugId":"lazertinib","nct":"NCT05786430","title":"Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib","phases":["PHASE2"],"sponsor":"Yonsei University","primaryCompletion":"2026-08-23","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"lazertinib","nct":"NCT05786430","title":"Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib","phases":["PHASE2"],"sponsor":"Yonsei University","primaryCompletion":"2026-08-23","kind":"primary-completion","from":"2026-08","to":"2026-08-23"},{"detected":"2026-10-12","drugId":"avutometinib-defactinib","nct":"NCT05787561","title":"A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-03","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"aumolertinib","nct":"NCT05810350","title":"Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles","phases":["PHASE2"],"sponsor":"Three Gorges Hospital of Chongqing University","primaryCompletion":"2025-08-31","kind":"status","from":"UNKNOWN","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"aumolertinib","nct":"NCT05810350","title":"Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles","phases":["PHASE2"],"sponsor":"Three Gorges Hospital of Chongqing University","primaryCompletion":"2025-08-31","kind":"primary-completion","from":"2024-12-31","to":"2025-08-31"},{"detected":"2026-10-12","drugId":"ivonescimab","nct":"NCT05899608","title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","phases":["PHASE3"],"sponsor":"Summit Therapeutics","primaryCompletion":"2028-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"teclistamab","nct":"NCT05932680","title":"Limited-duration Teclistamab","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2027-01","kind":"primary-completion","from":"2026-06","to":"2027-01"},{"detected":"2026-10-12","drugId":"golcadomide","nct":"NCT06035497","title":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","phases":["PHASE1","PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2026-08-11","kind":"primary-completion","from":"2027-01-30","to":"2026-08-11"},{"detected":"2026-10-12","drugId":"ramucirumab","nct":"NCT06038578","title":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","phases":["PHASE2"],"sponsor":"Toray Industries, Inc","primaryCompletion":"2027-10-31","kind":"primary-completion","from":"2026-06-30","to":"2027-10-31"},{"detected":"2026-10-12","drugId":"flot","nct":"NCT06044311","title":"Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma","phases":["PHASE2"],"sponsor":"Melissa Lumish","primaryCompletion":"2027-03","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"flot","nct":"NCT06044311","title":"Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma","phases":["PHASE2"],"sponsor":"Melissa Lumish","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-12-31","to":"2027-03"},{"detected":"2026-10-12","drugId":"tivozanib","nct":"NCT06053658","title":"Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-11-01","kind":"primary-completion","from":"2026-11-01","to":"2028-11-01"},{"detected":"2026-10-12","drugId":"envafolimab","nct":"NCT06055816","title":"Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma","phases":["PHASE2"],"sponsor":"Zhejiang Cancer Hospital","primaryCompletion":"2026-05-09","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"envafolimab","nct":"NCT06055816","title":"Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma","phases":["PHASE2"],"sponsor":"Zhejiang Cancer Hospital","primaryCompletion":"2026-05-09","kind":"primary-completion","from":"2024-09-30","to":"2026-05-09"},{"detected":"2026-10-12","drugId":"megestrol-progestins","nct":"NCT06073184","title":"Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium","phases":["PHASE2"],"sponsor":"GynOncTrials","primaryCompletion":"2029-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"megestrol-progestins","nct":"NCT06073184","title":"Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium","phases":["PHASE2"],"sponsor":"GynOncTrials","primaryCompletion":"2029-02","kind":"primary-completion","from":"2027-02","to":"2029-02"},{"detected":"2026-10-12","drugId":"olaparib","nct":"NCT06135714","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","phases":["PHASE3"],"sponsor":"Tokyo Medical and Dental University","primaryCompletion":"2029-11-08","kind":"primary-completion","from":"2026-11-08","to":"2029-11-08"},{"detected":"2026-10-12","drugId":"nimotuzumab","nct":"NCT06343116","title":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","phases":["PHASE3"],"sponsor":"Biotech Pharmaceutical Co., Ltd.","primaryCompletion":"2027-04","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-10-12","drugId":"calderasib","nct":"NCT06345729","title":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2028-01-24","kind":"primary-completion","from":"2029-02-19","to":"2028-01-24"},{"detected":"2026-10-12","drugId":"dronabinol","nct":"NCT06473701","title":"Reducing Breathlessness With Dronabinol in COPD Patients","phases":["PHASE3"],"sponsor":"Vejle Hospital","primaryCompletion":"2026-09-21","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"dronabinol","nct":"NCT06473701","title":"Reducing Breathlessness With Dronabinol in COPD Patients","phases":["PHASE3"],"sponsor":"Vejle Hospital","primaryCompletion":"2026-09-21","kind":"primary-completion","from":"2026-09","to":"2026-09-21"},{"detected":"2026-10-12","drugId":"izalontamab-brengitecan","nct":"NCT06498986","title":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"izalontamab-brengitecan","nct":"NCT06498986","title":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2027-06","kind":"primary-completion","from":"2026-08","to":"2027-06"},{"detected":"2026-10-12","drugId":"axicabtagene-ciloleucel","nct":"NCT06550141","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","phases":["PHASE2"],"sponsor":"Marcela V. Maus, M.D.,Ph.D.","primaryCompletion":"2027-08-01","kind":"primary-completion","from":"2026-08-01","to":"2027-08-01"},{"detected":"2026-10-12","drugId":"lisocabtagene-maraleucel","nct":"NCT06550141","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","phases":["PHASE2"],"sponsor":"Marcela V. Maus, M.D.,Ph.D.","primaryCompletion":"2027-08-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"talazoparib","nct":"NCT06582628","title":"Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"Fundacion Oncosur","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2026-01-31","to":"2027-12-31"},{"detected":"2026-10-12","drugId":"elacestrant","nct":"NCT06590857","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","phases":["PHASE1","PHASE2"],"sponsor":"RayzeBio, Inc.","primaryCompletion":"2028-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"bcg-intravesical","nct":"NCT06704191","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","phases":["PHASE1","PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2026-12-31","to":"2027-12-31"},{"detected":"2026-10-12","drugId":"mebendazole","nct":"NCT06736691","title":"Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections","phases":["PHASE3"],"sponsor":"Swiss Tropical & Public Health Institute","primaryCompletion":"2026-07-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"tarlatamab","nct":"NCT06745323","title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","phases":["PHASE2"],"sponsor":"Amgen","primaryCompletion":"2029-08-10","kind":"primary-completion","from":"2029-05-10","to":"2029-08-10"},{"detected":"2026-10-12","drugId":"palonosetron","nct":"NCT06766825","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","phases":["PHASE2"],"sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","primaryCompletion":"2026-09-29","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"palonosetron","nct":"NCT06766825","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","phases":["PHASE2"],"sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","primaryCompletion":"2026-09-29","kind":"primary-completion","from":"2026-09-10","to":"2026-09-29"},{"detected":"2026-10-12","drugId":"ifinatamab-deruxtecan","nct":"NCT06780137","title":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2029-02-15","kind":"primary-completion","from":"2029-04-27","to":"2029-02-15"},{"detected":"2026-10-12","drugId":"ifinatamab-deruxtecan","nct":"NCT06863272","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2031-10-01","kind":"primary-completion","from":"2031-04-01","to":"2031-10-01"},{"detected":"2026-10-12","drugId":"infigratinib","nct":"NCT06926491","title":"Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）","phases":["PHASE3"],"sponsor":"Kyowa Kirin Co., Ltd.","primaryCompletion":"2029-05-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"alpelisib","nct":"NCT06997588","title":"EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2029-01-29","kind":"primary-completion","from":"2028-08-02","to":"2029-01-29"},{"detected":"2026-10-12","drugId":"osimertinib","nct":"NCT07005102","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2036-11","kind":"primary-completion","from":"2031-12","to":"2036-11"},{"detected":"2026-10-12","drugId":"blinatumomab","nct":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"Amgen","primaryCompletion":"2031-03-06","kind":"primary-completion","from":"2028-12-05","to":"2031-03-06"},{"detected":"2026-10-12","drugId":"ivermectin","nct":"NCT07159373","title":"Better Options for Lymphatic Filariasis Treatment","phases":["PHASE3"],"sponsor":"Medicines Development for Global Health","primaryCompletion":"2027-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"jdq443","nct":"NCT07468071","title":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments","phases":["PHASE1","PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2029-06-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"bgb-16673","nct":"NCT07508995","title":"A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2031-07-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"mirdametinib","nct":"NCT07521657","title":"Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma","phases":["PHASE2"],"sponsor":"University of Alabama at Birmingham","primaryCompletion":"2031-01-01","kind":"primary-completion","from":"2030-08-01","to":"2031-01-01"},{"detected":"2026-10-12","drugId":"ficerafusp-alfa","nct":"NCT07529873","title":"Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","primaryCompletion":"2030-04","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"hepzato","nct":"NCT07582172","title":"Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2031-11-05","kind":"primary-completion","from":"2029-04-05","to":"2031-11-05"},{"detected":"2026-10-12","drugId":"iberdomide","nct":"NCT07624513","title":"D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM","phases":["PHASE3"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2033-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"izalontamab-brengitecan","nct":"NCT07680790","title":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)","phases":["PHASE3"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2031-12-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"belzutifan","nct":"NCT07700758","title":"A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2034-01-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"ivermectin","nct":"NCT07710638","title":"Efficacy of Ivermectin in the Treatment of Plane Warts","phases":["PHASE2"],"sponsor":"Al-Azhar University","primaryCompletion":"2026-07-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"ivermectin","nct":"NCT07710638","title":"Efficacy of Ivermectin in the Treatment of Plane Warts","phases":["PHASE2"],"sponsor":"Al-Azhar University","primaryCompletion":"2026-07-01","kind":"primary-completion","from":"2026-06-01","to":"2026-07-01"},{"detected":"2026-10-12","drugId":"lifileucel","nct":"NCT07741877","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma","phases":["PHASE2"],"sponsor":"Iovance Biotherapeutics, Inc.","primaryCompletion":"2033-09-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"crb-701","nct":"NCT07768189","title":"A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma","phases":["PHASE3"],"sponsor":"Corbus Pharmaceuticals Inc.","primaryCompletion":"2027-12","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"histamine-dihydrochloride","nct":"NCT07785609","title":"A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2031-09-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"telisotuzumab-adizutecan","nct":"NCT07821684","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2030-03","kind":"primary-completion","from":"2031-04","to":"2030-03"},{"detected":"2026-10-12","drugId":"trastuzumab-biosimilars","nct":"NCT07857226","title":"Trastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast Cancer","phases":["PHASE2"],"sponsor":"Hebei Medical University Fourth Hospital","primaryCompletion":"2028-06","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"rinatabart-sesutecan","nct":"NCT07859215","title":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer","phases":["PHASE3"],"sponsor":"Genmab","primaryCompletion":"2030-03","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"dostarlimab","nct":"NCT07860450","title":"Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer","phases":["PHASE1","PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2030-11-05","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"glucarpidase","nct":"NCT07860554","title":"Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"epcoritamab","nct":"NCT07860775","title":"Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.","phases":["PHASE2"],"sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","primaryCompletion":"2030-10-15","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"quizartinib","nct":"NCT07862517","title":"Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"vusolimogene-oderparepvec","nct":"NCT07862530","title":"Neoadjuvant RP2 + Nivolumab in Patients With Melanoma","phases":["PHASE2"],"sponsor":"Yana Najjar","primaryCompletion":"2028-02-27","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"inotuzumab-ozogamicin","nct":"NCT07862946","title":"Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia","phases":["PHASE2"],"sponsor":"PETHEMA Foundation","primaryCompletion":"2030-10-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"pemigatinib","nct":"NCT07862998","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy","phases":["PHASE2"],"sponsor":"Incyte Corporation","primaryCompletion":"2031-02-25","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"aumolertinib","nct":"NCT07863167","title":"An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.","phases":["PHASE2"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2028-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"enfortumab-vedotin","nct":"NCT07863765","title":"Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2030-05-05","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"trastuzumab-rezetecan","nct":"NCT07865611","title":"Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer","phases":["PHASE2"],"sponsor":"Tongji Hospital","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"dostarlimab","nct":"NCT07867002","title":"Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer","phases":["PHASE3"],"sponsor":"UNC Lineberger Comprehensive Cancer Center","primaryCompletion":"2032-10","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"degarelix","nct":"NCT01630967","title":"Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)","phases":["PHASE2"],"sponsor":"British Columbia Cancer Agency","primaryCompletion":"2013-12","kind":"status","from":"UNKNOWN","to":"WITHDRAWN"},{"detected":"2026-10-05","drugId":"dinutuximab","nct":"NCT01704716","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","phases":["PHASE3"],"sponsor":"St. Anna Kinderkrebsforschung","primaryCompletion":"2021-09-30","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"floxuridine","nct":"NCT01815359","title":"ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09","kind":"primary-completion","from":"2026-09","to":"2027-09"},{"detected":"2026-10-05","drugId":"adavosertib","nct":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2026-12-31","to":"2027-12-31"},{"detected":"2026-10-05","drugId":"ixazomib","nct":"NCT02542657","title":"Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma","phases":["PHASE1","PHASE2"],"sponsor":"Joseph Tuscano","primaryCompletion":"2025-08","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"folfirinox","nct":"NCT02980510","title":"Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients","phases":["PHASE2"],"sponsor":"UNICANCER","primaryCompletion":"2025-12","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"romidepsin","nct":"NCT03278782","title":"Study of Pembrolizumab (MK-3475) in Combination With Romidepsin","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2025-03-31","kind":"results-posted"},{"detected":"2026-10-05","drugId":"romidepsin","nct":"NCT03278782","title":"Study of Pembrolizumab (MK-3475) in Combination With Romidepsin","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2025-03-31","kind":"primary-completion","from":"2027-07-31","to":"2025-03-31"},{"detected":"2026-10-05","drugId":"lutathera","nct":"NCT03454763","title":"Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors","phases":["PHASE2"],"sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","primaryCompletion":"2025-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"acalabrutinib","nct":"NCT03516617","title":"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-11-11","kind":"primary-completion","from":"2027-03-15","to":"2028-11-11"},{"detected":"2026-10-05","drugId":"omacetaxine","nct":"NCT03564873","title":"Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS","phases":["PHASE1","PHASE2"],"sponsor":"University of Colorado, Denver","primaryCompletion":"2025-10-07","kind":"results-posted"},{"detected":"2026-10-05","drugId":"acalabrutinib","nct":"NCT03571568","title":"A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","phases":["PHASE1","PHASE2"],"sponsor":"BioInvent International AB","primaryCompletion":"2027-09-30","kind":"primary-completion","from":"2026-09-30","to":"2027-09-30"},{"detected":"2026-10-05","drugId":"adebrelimab","nct":"NCT03736863","title":"A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital of Zhengzhou University","primaryCompletion":"2021-06-20","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"adagrasib","nct":"NCT03994796","title":"Genetic Testing in Guiding Treatment for Patients With Brain Metastases","phases":["PHASE2"],"sponsor":"Alliance for Clinical Trials in Oncology","primaryCompletion":"2025-11-13","kind":"primary-completion","from":"2026-10","to":"2025-11-13"},{"detected":"2026-10-05","drugId":"cabozantinib","nct":"NCT04071223","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-07-27","kind":"primary-completion","from":"2026-10-01","to":"2026-07-27"},{"detected":"2026-10-05","drugId":"vepdegestrant","nct":"NCT04072952","title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Arvinas Estrogen Receptor, Inc.","primaryCompletion":"2024-09-13","kind":"results-posted"},{"detected":"2026-10-05","drugId":"pyrotinib","nct":"NCT04144569","title":"PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC","phases":["PHASE2"],"sponsor":"Yongchang Zhang","primaryCompletion":"2024-12-30","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"enb003","nct":"NCT04205227","title":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"ENB Therapeutics, Inc","primaryCompletion":"2026-01-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"glofitamab","nct":"NCT04231877","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2026-09-23","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"ramucirumab","nct":"NCT04310007","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-03-31","kind":"primary-completion","from":"2026-12-31","to":"2027-03-31"},{"detected":"2026-10-05","drugId":"tst001","nct":"NCT04396821","title":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Transcenta Therapeutics (Hangzhou) Co., Ltd.","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2026-05-30","to":"2027-06-30"},{"detected":"2026-10-05","drugId":"lerotinib","nct":"NCT04415853","title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","phases":["PHASE3"],"sponsor":"Sunshine Lake Pharma Co., Ltd.","primaryCompletion":"2027-08","kind":"primary-completion","from":"2026-08","to":"2027-08"},{"detected":"2026-10-05","drugId":"altretamine","nct":"NCT04476901","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","phases":["PHASE2"],"sponsor":"Joshua M Hare","primaryCompletion":"2027-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"acalabrutinib","nct":"NCT04484012","title":"Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-02-23","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"acalabrutinib","nct":"NCT04484012","title":"Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-02-23","kind":"primary-completion","from":"2026-09-02","to":"2027-02-23"},{"detected":"2026-10-05","drugId":"tst001","nct":"NCT04495296","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Transcenta Therapeutics (Hangzhou) Co., Ltd.","primaryCompletion":"2027-06-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"tst001","nct":"NCT04495296","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Transcenta Therapeutics (Hangzhou) Co., Ltd.","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2026-06-25","to":"2027-06-30"},{"detected":"2026-10-05","drugId":"tegafur-gimeracil-oteracil","nct":"NCT04515615","title":"Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)","phases":["PHASE2"],"sponsor":"Yu jiren","primaryCompletion":"2023-12-29","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"xzp-3287","nct":"NCT04539496","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","primaryCompletion":"2023-07-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"acalabrutinib","nct":"NCT04560322","title":"Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL","phases":["PHASE2"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2028-03-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"pylarify","nct":"NCT04573231","title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"University of Wisconsin, Madison","primaryCompletion":"2026-08-31","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"pylarify","nct":"NCT04573231","title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"University of Wisconsin, Madison","primaryCompletion":"2026-08-31","kind":"primary-completion","from":"2026-08","to":"2026-08-31"},{"detected":"2026-10-05","drugId":"pomalidomide","nct":"NCT04577755","title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-02-04","kind":"primary-completion","from":"2026-10-01","to":"2027-02-04"},{"detected":"2026-10-05","drugId":"signatera","nct":"NCT04660344","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-06-15","kind":"results-posted"},{"detected":"2026-10-05","drugId":"arsenic-trioxide","nct":"NCT04687176","title":"Frontline Oral Arsenic Trioxide for APL","phases":["PHASE2"],"sponsor":"The University of Hong Kong","primaryCompletion":"2025-12-31","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"anastrozole","nct":"NCT04711252","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2026-06-26","kind":"primary-completion","from":"2026-08-24","to":"2026-06-26"},{"detected":"2026-10-05","drugId":"imlunestrant","nct":"NCT04923542","title":"SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases","phases":["PHASE1","PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-07","kind":"primary-completion","from":"2026-11-05","to":"2027-07"},{"detected":"2026-10-05","drugId":"glofitamab","nct":"NCT04980222","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2024-10-24","kind":"primary-completion","from":"2024-09-24","to":"2024-10-24"},{"detected":"2026-10-05","drugId":"methoxsalen-ecp","nct":"NCT04986605","title":"Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2028-07","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"methoxsalen-ecp","nct":"NCT04986605","title":"Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2028-07","kind":"primary-completion","from":"2026-07","to":"2028-07"},{"detected":"2026-10-05","drugId":"vibostolimab","nct":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2025-08-05","kind":"results-posted"},{"detected":"2026-10-05","drugId":"hpv-quadrivalent-vaccine","nct":"NCT05027776","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","phases":["PHASE3"],"sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","primaryCompletion":"2023-11-22","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"nedaplatin","nct":"NCT05039606","title":"Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma","phases":["PHASE2"],"sponsor":"Guiyang Medical University","primaryCompletion":"2026-09","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"aminolevulinic-acid-gleolan","nct":"NCT05080764","title":"Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults","phases":["PHASE2"],"sponsor":"Biofrontera Inc.","primaryCompletion":"2025-08-22","kind":"results-posted"},{"detected":"2026-10-05","drugId":"tucatinib","nct":"NCT05132582","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","phases":["PHASE3"],"sponsor":"Seagen, a wholly owned subsidiary of Pfizer","primaryCompletion":"2025-09-05","kind":"results-posted"},{"detected":"2026-10-05","drugId":"brentuximab-vedotin","nct":"NCT05149768","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2025-07-23","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"brentuximab-vedotin","nct":"NCT05149768","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2025-07-23","kind":"primary-completion","from":"2026-02-14","to":"2025-07-23"},{"detected":"2026-10-05","drugId":"ga68-psma-11","nct":"NCT05176223","title":"68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2025-12-31","kind":"results-posted"},{"detected":"2026-10-05","drugId":"penpulimab","nct":"NCT05193617","title":"Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma","phases":["PHASE2"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2026-10-01","kind":"primary-completion","from":"2025-01-01","to":"2026-10-01"},{"detected":"2026-10-05","drugId":"imiquimod","nct":"NCT05212246","title":"Basal Cell Carcinoma Chemoprevention Trial","phases":["PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2032-10-05","kind":"primary-completion","from":"2032-09-21","to":"2032-10-05"},{"detected":"2026-10-05","drugId":"giredestrant","nct":"NCT05296798","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-06-15","kind":"primary-completion","from":"2027-10-31","to":"2028-06-15"},{"detected":"2026-10-05","drugId":"trifluridine-tipiracil","nct":"NCT05343013","title":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2027-05-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"binimetinib","nct":"NCT05370807","title":"A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma","phases":["PHASE2"],"sponsor":"Universitair Ziekenhuis Brussel","primaryCompletion":"2026-12","kind":"status","from":"UNKNOWN","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"binimetinib","nct":"NCT05370807","title":"A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma","phases":["PHASE2"],"sponsor":"Universitair Ziekenhuis Brussel","primaryCompletion":"2026-12","kind":"primary-completion","from":"2024-12","to":"2026-12"},{"detected":"2026-10-05","drugId":"furmonertinib","nct":"NCT05379803","title":"High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases","phases":["PHASE2"],"sponsor":"Hunan Province Tumor Hospital","primaryCompletion":"2024-12-31","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"nalirifox","nct":"NCT05482893","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","phases":["PHASE1","PHASE2"],"sponsor":"Phanes Therapeutics","primaryCompletion":"2027-12","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"apalutamide","nct":"NCT05534646","title":"Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc","phases":["PHASE2"],"sponsor":"Edwin Posadas, MD","primaryCompletion":"2028-01","kind":"primary-completion","from":"2027-01","to":"2028-01"},{"detected":"2026-10-05","drugId":"dronabinol","nct":"NCT05543681","title":"Clinical Trial on Agitation in Alzheimer's Dementia","phases":["PHASE2"],"sponsor":"IGC Pharma, LLC","primaryCompletion":"2026-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"dronabinol","nct":"NCT05543681","title":"Clinical Trial on Agitation in Alzheimer's Dementia","phases":["PHASE2"],"sponsor":"IGC Pharma, LLC","primaryCompletion":"2026-11","kind":"primary-completion","from":"2026-08","to":"2026-11"},{"detected":"2026-10-05","drugId":"cpx-351","nct":"NCT05554419","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2030-12-31","kind":"primary-completion","from":"2026-08-31","to":"2030-12-31"},{"detected":"2026-10-05","drugId":"imetelstat","nct":"NCT05583552","title":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","phases":["PHASE2"],"sponsor":"GCP-Service International West GmbH","primaryCompletion":"2025-03-27","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"zynlonta","nct":"NCT05600686","title":"Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","phases":["PHASE2"],"sponsor":"University of California, Davis","primaryCompletion":"2026-10-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"capox","nct":"NCT05628038","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2024-12-01","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"pamiparib","nct":"NCT05652283","title":"Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","phases":["PHASE2"],"sponsor":"Bai-Rong Xia","primaryCompletion":"2027-03","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"pamiparib","nct":"NCT05652283","title":"Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","phases":["PHASE2"],"sponsor":"Bai-Rong Xia","primaryCompletion":"2027-03","kind":"primary-completion","from":"2024-05-31","to":"2027-03"},{"detected":"2026-10-05","drugId":"lisocabtagene-maraleucel","nct":"NCT05672173","title":"Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-08-24","kind":"primary-completion","from":"2026-09-10","to":"2027-08-24"},{"detected":"2026-10-05","drugId":"tafasitamab","nct":"NCT05718869","title":"Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-07-27","kind":"primary-completion","from":"2026-09-08","to":"2027-07-27"},{"detected":"2026-10-05","drugId":"tst003","nct":"NCT05731271","title":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Transcenta Therapeutics (Hangzhou) Co., Ltd.","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2026-06","to":"2027-06-30"},{"detected":"2026-10-05","drugId":"shr-a1921","nct":"NCT05765032","title":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2025-04-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"abemaciclib","nct":"NCT05766410","title":"A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC","phases":["PHASE2"],"sponsor":"National Taiwan University Hospital","primaryCompletion":"2025-09-30","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"tiragolumab","nct":"NCT05798663","title":"Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC","phases":["PHASE2"],"sponsor":"Alliance Foundation Trials, LLC.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-11","to":"2027-02"},{"detected":"2026-10-05","drugId":"amivantamab","nct":"NCT05845671","title":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","phases":["PHASE1","PHASE2"],"sponsor":"University of Colorado, Denver","primaryCompletion":"2026-09-23","kind":"primary-completion","from":"2027-01","to":"2026-09-23"},{"detected":"2026-10-05","drugId":"balstilimab","nct":"NCT05864534","title":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2031-07-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"belantamab-mafodotin","nct":"NCT05874193","title":"A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma","phases":["PHASE2"],"sponsor":"Cristiana Costa Chase, DO","primaryCompletion":"2028-10","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-10-05","drugId":"ondansetron","nct":"NCT05876585","title":"Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis","phases":["PHASE3"],"sponsor":"Genuine Research Center, Egypt","primaryCompletion":"2025-06-01","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"lurbinectedin","nct":"NCT05876715","title":"LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma","phases":["PHASE1","PHASE2"],"sponsor":"ERLINDA M GORDON","primaryCompletion":"2026-06-30","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"luspatercept","nct":"NCT05925504","title":"The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2026-06-30","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"cadonilimab","nct":"NCT05932212","title":"AK104 for Recurrent or Metastatic Vulvar Cancer","phases":["PHASE2"],"sponsor":"Akeso","primaryCompletion":"2026-05-31","kind":"status","from":"RECRUITING","to":"TERMINATED"},{"detected":"2026-10-05","drugId":"cadonilimab","nct":"NCT05932212","title":"AK104 for Recurrent or Metastatic Vulvar Cancer","phases":["PHASE2"],"sponsor":"Akeso","primaryCompletion":"2026-05-31","kind":"primary-completion","from":"2025-12-15","to":"2026-05-31"},{"detected":"2026-10-05","drugId":"eltrombopag","nct":"NCT05961410","title":"Eltrombopag for Peripheral Blood Stem Cell Harvest","phases":["PHASE2"],"sponsor":"National Taiwan University Hospital","primaryCompletion":"2025-03-31","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"rc118-adc","nct":"NCT06038396","title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2026-02-28","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"penpulimab","nct":"NCT06048315","title":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody","phases":["PHASE3"],"sponsor":"Degan Lu","primaryCompletion":"2026-06","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"blinatumomab","nct":"NCT06075238","title":"Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT","phases":["PHASE2"],"sponsor":"Sichuan University","primaryCompletion":"2024-09-30","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"flot","nct":"NCT06078709","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2029-05-25","kind":"primary-completion","from":"2027-05-30","to":"2029-05-25"},{"detected":"2026-10-05","drugId":"anagrelide","nct":"NCT06079879","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2027-07-14","kind":"primary-completion","from":"2027-07-30","to":"2027-07-14"},{"detected":"2026-10-05","drugId":"penpulimab","nct":"NCT06081673","title":"Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC","phases":["PHASE2"],"sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","primaryCompletion":"2026-12-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"penpulimab","nct":"NCT06081673","title":"Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC","phases":["PHASE2"],"sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","primaryCompletion":"2026-12-30","kind":"primary-completion","from":"2024-12-30","to":"2026-12-30"},{"detected":"2026-10-05","drugId":"toripalimab","nct":"NCT06093438","title":"Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Tianjin Medical University Cancer Institute and Hospital","primaryCompletion":"2025-11-01","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"samuraciclib","nct":"NCT06125522","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2026-09-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"samuraciclib","nct":"NCT06125522","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2026-09-10","kind":"primary-completion","from":"2026-12-31","to":"2026-09-10"},{"detected":"2026-10-05","drugId":"vepdegestrant","nct":"NCT06206837","title":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2025-09-05","kind":"results-posted"},{"detected":"2026-10-05","drugId":"binimetinib","nct":"NCT06229340","title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","phases":["PHASE2"],"sponsor":"N.N. Petrov National Medical Research Center of Oncology","primaryCompletion":"2026-10-01","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"futibatinib","nct":"NCT06263153","title":"Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy","phases":["PHASE2"],"sponsor":"Yuanquan Yang","primaryCompletion":"2027-07-31","kind":"primary-completion","from":"2026-12-31","to":"2027-07-31"},{"detected":"2026-10-05","drugId":"regorafenib","nct":"NCT06275919","title":"Regorafenib for Recurrent Meningioma (MIRAGE Trial)","phases":["PHASE2"],"sponsor":"Istituto Oncologico Veneto IRCCS","primaryCompletion":"2028-12","kind":"primary-completion","from":"2026-12","to":"2028-12"},{"detected":"2026-10-05","drugId":"surufatinib","nct":"NCT06329947","title":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","phases":["PHASE2"],"sponsor":"Rui-hua Xu, MD, PhD","primaryCompletion":"2025-01-01","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"ugn-103","nct":"NCT06331299","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","phases":["PHASE3"],"sponsor":"UroGen Pharma Ltd.","primaryCompletion":"2025-09-11","kind":"results-posted"},{"detected":"2026-10-05","drugId":"ifinatamab-deruxtecan","nct":"NCT06362252","title":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)","phases":["PHASE1","PHASE2"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2027-07-20","kind":"primary-completion","from":"2026-09-30","to":"2027-07-20"},{"detected":"2026-10-05","drugId":"furmonertinib","nct":"NCT06394674","title":"High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib","phases":["PHASE2"],"sponsor":"Changhai Hospital","primaryCompletion":"2025-06","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"isotretinoin","nct":"NCT06447480","title":"Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients","phases":["PHASE3"],"sponsor":"Centre Hospitalier Universitaire de Nice","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2026-09-01","to":"2027-09-01"},{"detected":"2026-10-05","drugId":"tqb2450","nct":"NCT06469879","title":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","phases":["PHASE3"],"sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","primaryCompletion":"2026-09","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"vorolanib","nct":"NCT06523049","title":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","phases":["PHASE2"],"sponsor":"Hao Zeng","primaryCompletion":"2026-07","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"furmonertinib","nct":"NCT06537297","title":"Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases","phases":["PHASE2"],"sponsor":"Hunan Province Tumor Hospital","primaryCompletion":"2025-08-31","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"fluzoparib","nct":"NCT06539091","title":"Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer","phases":["PHASE3"],"sponsor":"Anhui Provincial Hospital","primaryCompletion":"2025-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"hydroxyurea","nct":"NCT06578507","title":"Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease","phases":["PHASE2"],"sponsor":"Theravia","primaryCompletion":"2028-02","kind":"primary-completion","from":"2027-02","to":"2028-02"},{"detected":"2026-10-05","drugId":"cadonilimab","nct":"NCT06586294","title":"A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Akeso","primaryCompletion":"2026-07","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"shr-8068","nct":"NCT06589778","title":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","primaryCompletion":"2026-04-30","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"dolasetron","nct":"NCT06593782","title":"Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting","phases":["PHASE2"],"sponsor":"First Affiliated Hospital of Wenzhou Medical University","primaryCompletion":"2025-06-11","kind":"status","from":"NOT_YET_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"patritumab-deruxtecan","nct":"NCT06596694","title":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2028-12-07","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"romiplostim","nct":"NCT06613880","title":"Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2026-01-31","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"rinatabart-sesutecan","nct":"NCT06619236","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","phases":["PHASE3"],"sponsor":"Genmab","primaryCompletion":"2026-08-18","kind":"primary-completion","from":"2027-02","to":"2026-08-18"},{"detected":"2026-10-05","drugId":"selumetinib","nct":"NCT06727357","title":"Next Generation Sequencing-based \"Oncochip\" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP","phases":["PHASE2"],"sponsor":"European Institute of Oncology","primaryCompletion":"2025-03","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"cabazitaxel","nct":"NCT06738303","title":"Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"Case Comprehensive Cancer Center","primaryCompletion":"2028-02-20","kind":"primary-completion","from":"2026-12","to":"2028-02-20"},{"detected":"2026-10-05","drugId":"crisantaspase","nct":"NCT06738368","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2028-01-31","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-10-05","drugId":"sacituzumab-tirumotecan","nct":"NCT06788912","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-02-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"asciminib","nct":"NCT06817720","title":"Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2027-03-07","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"golcadomide","nct":"NCT06834373","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2027-06-10","kind":"primary-completion","from":"2027-03-03","to":"2027-06-10"},{"detected":"2026-10-05","drugId":"cemiplimab","nct":"NCT06918132","title":"Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2030-12-02","kind":"primary-completion","from":"2027-04-29","to":"2030-12-02"},{"detected":"2026-10-05","drugId":"acasunlimab","nct":"NCT06984328","title":"Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)","phases":["PHASE2"],"sponsor":"Genmab","primaryCompletion":"2026-05-15","kind":"results-posted"},{"detected":"2026-10-05","drugId":"hrs-8080","nct":"NCT07024173","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","phases":["PHASE3"],"sponsor":"Shandong Suncadia Medicine Co., Ltd.","primaryCompletion":"2027-08","kind":"primary-completion","from":"2026-12","to":"2027-08"},{"detected":"2026-10-05","drugId":"amivantamab","nct":"NCT07042295","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-02-28","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"epcoritamab","nct":"NCT07126236","title":"Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma","phases":["PHASE2"],"sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","primaryCompletion":"2031-12-27","kind":"primary-completion","from":"2031-12","to":"2031-12-27"},{"detected":"2026-10-05","drugId":"cmg901","nct":"NCT07143604","title":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","phases":["PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2026-08-14","kind":"primary-completion","from":"2026-09-28","to":"2026-08-14"},{"detected":"2026-10-05","drugId":"neratinib","nct":"NCT07152782","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-08","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"neratinib","nct":"NCT07152782","title":"T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-08","kind":"primary-completion","from":"2027-11","to":"2029-08"},{"detected":"2026-10-05","drugId":"tivozanib","nct":"NCT07218692","title":"RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-08-11","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-10-05","drugId":"pf-08634404","nct":"NCT07222800","title":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","phases":["PHASE3"],"sponsor":"Pfizer","primaryCompletion":"2030-02-23","kind":"primary-completion","from":"2030-03-29","to":"2030-02-23"},{"detected":"2026-10-05","drugId":"lifileucel","nct":"NCT07288203","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","phases":["PHASE2"],"sponsor":"Iovance Biotherapeutics, Inc.","primaryCompletion":"2027-12","kind":"primary-completion","from":"2032-12","to":"2027-12"},{"detected":"2026-10-05","drugId":"dronabinol","nct":"NCT07296874","title":"Acute Effects of Cannabis on Cognition and Affect","phases":["PHASE2"],"sponsor":"Washington State University","primaryCompletion":"2028-05","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"ql2107","nct":"NCT07301268","title":"GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2029-09-01","kind":"primary-completion","from":"2029-04-30","to":"2029-09-01"},{"detected":"2026-10-05","drugId":"azd9750","nct":"NCT07336446","title":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2026-11-05","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"azd9750","nct":"NCT07336446","title":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2026-11-05","kind":"primary-completion","from":"2029-01-26","to":"2026-11-05"},{"detected":"2026-10-05","drugId":"iparomlimab-tuvonralimab","nct":"NCT07372079","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","phases":["PHASE2"],"sponsor":"Tianjin Medical University Cancer Institute and Hospital","primaryCompletion":"2028-12-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"pf-08634404","nct":"NCT07392892","title":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","phases":["PHASE2","PHASE3"],"sponsor":"Pfizer","primaryCompletion":"2032-01-15","kind":"primary-completion","from":"2031-07-22","to":"2032-01-15"},{"detected":"2026-10-05","drugId":"enfortumab-vedotin","nct":"NCT07421700","title":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-12-28","kind":"primary-completion","from":"2027-12-06","to":"2027-12-28"},{"detected":"2026-10-05","drugId":"dalpiciclib","nct":"NCT07432178","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","phases":["PHASE3"],"sponsor":"Fudan University","primaryCompletion":"2031-03-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"trilaciclib","nct":"NCT07473128","title":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Pharmacosmos A/S","primaryCompletion":"2027-10-31","kind":"primary-completion","from":"2027-06","to":"2027-10-31"},{"detected":"2026-10-05","drugId":"pf-08634404","nct":"NCT07476287","title":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2028-03-24","kind":"primary-completion","from":"2028-03-19","to":"2028-03-24"},{"detected":"2026-10-05","drugId":"disitamab-vedotin","nct":"NCT07498907","title":"Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma","phases":["PHASE3"],"sponsor":"Peking University First Hospital","primaryCompletion":"2029-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"pancrelipase","nct":"NCT07559175","title":"A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.","phases":["PHASE2"],"sponsor":"Aimmune Nestlé Health Science US R&D, LLC","primaryCompletion":"2027-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"nemtabrutinib","nct":"NCT07583810","title":"Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2028-05-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"flot","nct":"NCT07603375","title":"Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma","phases":["PHASE2"],"sponsor":"Duke University","primaryCompletion":"2029-08-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"belumosudil","nct":"NCT07643025","title":"Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)","phases":["PHASE2"],"sponsor":"Dennis Kim","primaryCompletion":"2029-11","kind":"primary-completion","from":"2029-07","to":"2029-11"},{"detected":"2026-10-05","drugId":"patritumab-deruxtecan","nct":"NCT07701941","title":"A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2031-01-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"bomedemstat","nct":"NCT07722611","title":"A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)","phases":["PHASE2","PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-06-25","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"izalontamab-brengitecan","nct":"NCT07729956","title":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)","phases":["PHASE3"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2029-12","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"isatuximab","nct":"NCT07732712","title":"Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells","phases":["PHASE2","PHASE3"],"sponsor":"The Affiliated People's Hospital of Ningbo University","primaryCompletion":"2028-12-31","kind":"primary-completion","from":"2028-08-01","to":"2028-12-31"},{"detected":"2026-10-05","drugId":"telisotuzumab-adizutecan","nct":"NCT07744126","title":"A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"AbbVie","primaryCompletion":"2029-10","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"axicabtagene-ciloleucel","nct":"NCT07763210","title":"Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma","phases":["PHASE2"],"sponsor":"Vanderbilt-Ingram Cancer Center","primaryCompletion":"2028-03-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"gfh375","nct":"NCT07784374","title":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation","phases":["PHASE2"],"sponsor":"Genfleet Therapeutics (Shanghai) Inc.","primaryCompletion":"2028-08-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"enzalutamide","nct":"NCT07802704","title":"A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]","phases":["PHASE3"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-12-05","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"enzalutamide","nct":"NCT07802704","title":"A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]","phases":["PHASE3"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-12-05","kind":"primary-completion","from":"2029-12-19","to":"2029-12-05"},{"detected":"2026-10-05","drugId":"zanubrutinib","nct":"NCT07839247","title":"Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL","phases":["PHASE2"],"sponsor":"Xiaohui Ren","primaryCompletion":"2027-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"nedaplatin","nct":"NCT07843303","title":"Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer","phases":["PHASE2"],"sponsor":"Peking University Cancer Hospital & Institute","primaryCompletion":"2028-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"larotrectinib","nct":"NCT07843550","title":"A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2027-07-13","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"velzatinib","nct":"NCT07843641","title":"A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)","phases":["PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2031-01-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"obrixtamig","nct":"NCT07843940","title":"A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)","phases":["PHASE1","PHASE2"],"sponsor":"Boehringer Ingelheim","primaryCompletion":"2030-04-17","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"tqb2922","nct":"NCT07844187","title":"TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread","phases":["PHASE1","PHASE2"],"sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","primaryCompletion":"2027-08-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"belantamab-mafodotin","nct":"NCT07844200","title":"The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.","phases":["PHASE2"],"sponsor":"Medical Association for the Study of Cancer Biology and Treatment","primaryCompletion":"2030-02","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"mrg003","nct":"NCT07844551","title":"ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC","phases":["PHASE2"],"sponsor":"Huashan Hospital","primaryCompletion":"2028-10-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"zanzalintinib","nct":"NCT07845786","title":"Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)","phases":["PHASE2"],"sponsor":"Exelixis","primaryCompletion":"2028-06-15","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"tqb2868","nct":"NCT07846267","title":"Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-10-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"retlirafusp-alfa","nct":"NCT07847710","title":"Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital with Nanjing Medical University","primaryCompletion":"2028-03-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"roginolisib","nct":"NCT07847957","title":"Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL","phases":["PHASE1","PHASE2"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2027-04-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"palonosetron","nct":"NCT07848984","title":"Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer","phases":["PHASE2"],"sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","primaryCompletion":"2028-08","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"atrasentan","nct":"NCT07850752","title":"A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy","phases":["PHASE3"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2028-09-17","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"sacituzumab-tirumotecan","nct":"NCT07850791","title":"A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer","phases":["PHASE2"],"sponsor":"Haitao Zhao, MD","primaryCompletion":"2028-10","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"azd5335","nct":"NCT07851025","title":"Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2030-06-18","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"envafolimab","nct":"NCT07852091","title":"A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)","phases":["PHASE2"],"sponsor":"The Second Affiliated Hospital of Chongqing Medical University","primaryCompletion":"2026-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"darolutamide","nct":"NCT07852195","title":"Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer","phases":["PHASE2","PHASE3"],"sponsor":"ECOG-ACRIN Cancer Research Group","primaryCompletion":"2029-03-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"dinutuximab","nct":"NCT07853105","title":"Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.","phases":["PHASE1","PHASE2"],"sponsor":"University Hospital, Strasbourg, France","primaryCompletion":"2031-02","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"sacituzumab-tirumotecan","nct":"NCT07854509","title":"A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure","phases":["PHASE2"],"sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","primaryCompletion":"2027-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"romiplostim","nct":"NCT07854561","title":"Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents","phases":["PHASE2"],"sponsor":"Chinese University of Hong Kong","primaryCompletion":"2027-02-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"nalirifox","nct":"NCT07854977","title":"Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.","phases":["PHASE2"],"sponsor":"Tianjin Medical University Cancer Institute and Hospital","primaryCompletion":"2029-05","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"plerixafor","nct":"NCT00967785","title":"A Phase I Study of Mozobil in the Treatment of Patients With WHIMS","phases":["PHASE1","PHASE2"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2026-06-25","kind":"primary-completion","from":"2026-08-06","to":"2026-06-25"},{"detected":"2026-09-28","drugId":"raloxifene","nct":"NCT02188745","title":"ER Reactivation Therapy for Breast Cancer","phases":["PHASE2"],"sponsor":"Dartmouth-Hitchcock Medical Center","primaryCompletion":"2024-01-05","kind":"results-posted"},{"detected":"2026-09-28","drugId":"blinatumomab","nct":"NCT02458014","title":"Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2025-09-16","kind":"results-posted"},{"detected":"2026-09-28","drugId":"entrectinib","nct":"NCT02650401","title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2026-06-30","to":"2027-06-30"},{"detected":"2026-09-28","drugId":"gilteritinib","nct":"NCT03182244","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","phases":["PHASE3"],"sponsor":"Astellas Pharma Inc","primaryCompletion":"2023-12-25","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"envafolimab","nct":"NCT03478488","title":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","phases":["PHASE3"],"sponsor":"3D Medicines (Sichuan) Co., Ltd.","primaryCompletion":"2024-09-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT03568656","title":"Study to Evaluate CCS1477 in Advanced Tumours","phases":["PHASE1","PHASE2"],"sponsor":"CellCentric Ltd.","primaryCompletion":"2025-07-06","kind":"results-posted"},{"detected":"2026-09-28","drugId":"avelumab","nct":"NCT03573648","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","phases":["PHASE2"],"sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","primaryCompletion":"2026-12-30","kind":"primary-completion","from":"2026-09-30","to":"2026-12-30"},{"detected":"2026-09-28","drugId":"eprenetapopt","nct":"NCT03588078","title":"Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine","phases":["PHASE1","PHASE2"],"sponsor":"Groupe Francophone des Myelodysplasies","primaryCompletion":"2020-05-01","kind":"status","from":"UNKNOWN","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"cediranib","nct":"NCT03741426","title":"WIRE - Novel Treatments in Renal Cell Cancer","phases":["PHASE2"],"sponsor":"CCTU- Cancer Theme","primaryCompletion":"2027-12-30","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"cediranib","nct":"NCT03741426","title":"WIRE - Novel Treatments in Renal Cell Cancer","phases":["PHASE2"],"sponsor":"CCTU- Cancer Theme","primaryCompletion":"2027-12-30","kind":"primary-completion","from":"2025-11-30","to":"2027-12-30"},{"detected":"2026-09-28","drugId":"rilvegostomig","nct":"NCT03741426","title":"WIRE - Novel Treatments in Renal Cell Cancer","phases":["PHASE2"],"sponsor":"CCTU- Cancer Theme","primaryCompletion":"2027-12-30","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT03969706","title":"Abemaciclib in Patients With Oligodendroglioma","phases":["PHASE2"],"sponsor":"Stephen Bagley, MD, MSCE","primaryCompletion":"2024-09-15","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT03969706","title":"Abemaciclib in Patients With Oligodendroglioma","phases":["PHASE2"],"sponsor":"Stephen Bagley, MD, MSCE","primaryCompletion":"2024-09-15","kind":"results-posted"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT03969706","title":"Abemaciclib in Patients With Oligodendroglioma","phases":["PHASE2"],"sponsor":"Stephen Bagley, MD, MSCE","primaryCompletion":"2024-09-15","kind":"primary-completion","from":"2025-05-15","to":"2024-09-15"},{"detected":"2026-09-28","drugId":"carfilzomib","nct":"NCT04096066","title":"A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant","phases":["PHASE3"],"sponsor":"Fondazione EMN Italy Onlus","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2026-01-01","to":"2027-09-01"},{"detected":"2026-09-28","drugId":"denosumab","nct":"NCT04232657","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","phases":["PHASE2"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-08-24","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"denosumab","nct":"NCT04232657","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","phases":["PHASE2"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-08-24","kind":"primary-completion","from":"2026-08-01","to":"2026-08-24"},{"detected":"2026-09-28","drugId":"darolutamide","nct":"NCT04335682","title":"Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide","phases":["PHASE2"],"sponsor":"Alliance Foundation Trials, LLC.","primaryCompletion":"2025-09-01","kind":"results-posted"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04489771","title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2023-02-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"metyrapone","nct":"NCT04501874","title":"A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder","phases":["PHASE2"],"sponsor":"Embera NeuroTherapeutics, Inc.","primaryCompletion":"2022-07-27","kind":"results-posted"},{"detected":"2026-09-28","drugId":"lipegfilgrastim","nct":"NCT04506554","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","phases":["PHASE2"],"sponsor":"Fox Chase Cancer Center","primaryCompletion":"2027-05","kind":"primary-completion","from":"2026-05","to":"2027-05"},{"detected":"2026-09-28","drugId":"motixafortide","nct":"NCT04543071","title":"Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma","phases":["PHASE2"],"sponsor":"Columbia University","primaryCompletion":"2028-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"dostarlimab","nct":"NCT04584255","title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","phases":["PHASE2"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2025-07-01","kind":"results-posted"},{"detected":"2026-09-28","drugId":"fianlimab","nct":"NCT04590326","title":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab","phases":["PHASE1","PHASE2"],"sponsor":"Regeneron Pharmaceuticals","primaryCompletion":"2028-11-08","kind":"primary-completion","from":"2027-03-25","to":"2028-11-08"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626479","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-08-10","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626479","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-08-10","kind":"primary-completion","from":"2026-08-21","to":"2026-08-10"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626518","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-07-23","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04626518","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","phases":["PHASE1","PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2026-07-23","kind":"primary-completion","from":"2026-08-21","to":"2026-07-23"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT04662255","title":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","phases":["PHASE3"],"sponsor":"Loxo Oncology, Inc.","primaryCompletion":"2027-11","kind":"primary-completion","from":"2027-01","to":"2027-11"},{"detected":"2026-09-28","drugId":"polatuzumab-vedotin","nct":"NCT04679012","title":"Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation","phases":["PHASE2"],"sponsor":"Weill Medical College of Cornell University","primaryCompletion":"2027-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"polatuzumab-vedotin","nct":"NCT04679012","title":"Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation","phases":["PHASE2"],"sponsor":"Weill Medical College of Cornell University","primaryCompletion":"2027-01","kind":"primary-completion","from":"2026-09","to":"2027-01"},{"detected":"2026-09-28","drugId":"belantamab-mafodotin","nct":"NCT04876248","title":"Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant","phases":["PHASE2"],"sponsor":"Roswell Park Cancer Institute","primaryCompletion":"2027-07-29","kind":"primary-completion","from":"2026-10-21","to":"2027-07-29"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-11-18","kind":"primary-completion","from":"2029-12-27","to":"2032-11-18"},{"detected":"2026-09-28","drugId":"asciminib","nct":"NCT04925479","title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2027-09-02","kind":"primary-completion","from":"2027-09-21","to":"2027-09-02"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT05023980","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","phases":["PHASE3"],"sponsor":"Loxo Oncology, Inc.","primaryCompletion":"2025-07-11","kind":"results-posted"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05083169","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE3"],"sponsor":"Janssen Research & Development, LLC","primaryCompletion":"2025-08-01","kind":"primary-completion","from":"2025-09-15","to":"2025-08-01"},{"detected":"2026-09-28","drugId":"acasunlimab","nct":"NCT05117242","title":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","phases":["PHASE2"],"sponsor":"Genmab","primaryCompletion":"2024-12-02","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-09-28","drugId":"jdq443","nct":"NCT05132075","title":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2026-09-03","kind":"primary-completion","from":"2026-08-25","to":"2026-09-03"},{"detected":"2026-09-28","drugId":"zanidatamab","nct":"NCT05152147","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","phases":["PHASE3"],"sponsor":"Jazz Pharmaceuticals","primaryCompletion":"2026-07-15","kind":"primary-completion","from":"2026-09-30","to":"2026-07-15"},{"detected":"2026-09-28","drugId":"histamine-dihydrochloride","nct":"NCT05156047","title":"A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia","phases":["PHASE3"],"sponsor":"Harmony Biosciences Management, Inc.","primaryCompletion":"2023-09-08","kind":"results-posted"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05231629","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","phases":["PHASE2"],"sponsor":"University of Alabama at Birmingham","primaryCompletion":"2028-09","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05231629","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","phases":["PHASE2"],"sponsor":"University of Alabama at Birmingham","primaryCompletion":"2028-09","kind":"primary-completion","from":"2027-12","to":"2028-09"},{"detected":"2026-09-28","drugId":"relacorilant","nct":"NCT05257408","title":"Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","phases":["PHASE3"],"sponsor":"Corcept Therapeutics","primaryCompletion":"2025-03-31","kind":"results-posted"},{"detected":"2026-09-28","drugId":"relacorilant","nct":"NCT05257408","title":"Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","phases":["PHASE3"],"sponsor":"Corcept Therapeutics","primaryCompletion":"2025-03-31","kind":"primary-completion","from":"2025-03-24","to":"2025-03-31"},{"detected":"2026-09-28","drugId":"retifanlimab","nct":"NCT05287113","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE2"],"sponsor":"Incyte Biosciences International Sàrl","primaryCompletion":"2025-03-14","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"talazoparib","nct":"NCT05327010","title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"sonrotoclax","nct":"NCT05471843","title":"Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2025-07-18","kind":"results-posted"},{"detected":"2026-09-28","drugId":"breast-cancer-index","nct":"NCT05528133","title":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2029-09","kind":"primary-completion","from":"2028-05","to":"2029-09"},{"detected":"2026-09-28","drugId":"mezigdomide","nct":"NCT05552976","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","phases":["PHASE3"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2026-09-28","kind":"primary-completion","from":"2026-07-18","to":"2026-09-28"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05572229","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","phases":["PHASE2"],"sponsor":"University Hospital, Lille","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"teclistamab","nct":"NCT05572229","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","phases":["PHASE2"],"sponsor":"University Hospital, Lille","primaryCompletion":"2027-06","kind":"primary-completion","from":"2026-04","to":"2027-06"},{"detected":"2026-09-28","drugId":"abemaciclib","nct":"NCT05708235","title":"A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population","phases":["PHASE2"],"sponsor":"MedSIR","primaryCompletion":"2028-06-30","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"pyrotinib","nct":"NCT05745740","title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","phases":["PHASE1","PHASE2"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2027-12-01","kind":"status","from":"UNKNOWN","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"pyrotinib","nct":"NCT05745740","title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","phases":["PHASE1","PHASE2"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2027-12-01","kind":"primary-completion","from":"2025-12","to":"2027-12-01"},{"detected":"2026-09-28","drugId":"envafolimab","nct":"NCT05752136","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","phases":["PHASE3"],"sponsor":"Sir Run Run Shaw Hospital","primaryCompletion":"2026-11-01","kind":"primary-completion","from":"2025-04","to":"2026-11-01"},{"detected":"2026-09-28","drugId":"glofitamab","nct":"NCT05783596","title":"Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma","phases":["PHASE2"],"sponsor":"Reid Merryman, MD","primaryCompletion":"2026-05-27","kind":"primary-completion","from":"2026-08","to":"2026-05-27"},{"detected":"2026-09-28","drugId":"glofitamab","nct":"NCT05861050","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2027-02-01","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-28","drugId":"azd5863","nct":"NCT06005493","title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2029-03-16","kind":"primary-completion","from":"2027-07-16","to":"2029-03-16"},{"detected":"2026-09-28","drugId":"rilvegostomig","nct":"NCT06005493","title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2029-03-16","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"memantine","nct":"NCT06041789","title":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","phases":["PHASE2"],"sponsor":"Duke University","primaryCompletion":"2027-09","kind":"primary-completion","from":"2026-11","to":"2027-09"},{"detected":"2026-09-28","drugId":"dostarlimab","nct":"NCT06062420","title":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","phases":["PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2026-09-10","kind":"primary-completion","from":"2026-09-01","to":"2026-09-10"},{"detected":"2026-09-28","drugId":"budigalimab","nct":"NCT06109272","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2027-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"budigalimab","nct":"NCT06109272","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2027-01","kind":"primary-completion","from":"2030-09","to":"2027-01"},{"detected":"2026-09-28","drugId":"crizotinib","nct":"NCT06140836","title":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","phases":["PHASE3"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2027-02-16","kind":"primary-completion","from":"2026-03-13","to":"2027-02-16"},{"detected":"2026-09-28","drugId":"brexucabtagene-autoleucel","nct":"NCT06144606","title":"Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2031-07-29","kind":"primary-completion","from":"2028-11-15","to":"2031-07-29"},{"detected":"2026-09-28","drugId":"zongertinib","nct":"NCT06151574","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","phases":["PHASE3"],"sponsor":"Boehringer Ingelheim","primaryCompletion":"2026-12-10","kind":"primary-completion","from":"2026-09-02","to":"2026-12-10"},{"detected":"2026-09-28","drugId":"daratumumab","nct":"NCT06169215","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-04-15","kind":"primary-completion","from":"2026-09-30","to":"2026-04-15"},{"detected":"2026-09-28","drugId":"bendamustine","nct":"NCT06284122","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","phases":["PHASE3"],"sponsor":"The Lymphoma Academic Research Organisation","primaryCompletion":"2028-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-07-29","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-07-29","kind":"primary-completion","from":"2027-04-22","to":"2028-07-29"},{"detected":"2026-09-28","drugId":"dalpiciclib","nct":"NCT06447623","title":"Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer","phases":["PHASE3"],"sponsor":"Fudan University","primaryCompletion":"2027-02-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"petosemtamab","nct":"NCT06525220","title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","phases":["PHASE3"],"sponsor":"Merus B.V.","primaryCompletion":"2028-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"epcoritamab","nct":"NCT06563596","title":"Epco, Zanu, Ritux for R/R FL or MZL","phases":["PHASE2"],"sponsor":"Reid Merryman, MD","primaryCompletion":"2030-03-01","kind":"primary-completion","from":"2028-03-01","to":"2030-03-01"},{"detected":"2026-09-28","drugId":"datopotamab-deruxtecan","nct":"NCT06564844","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2026-07-10","kind":"primary-completion","from":"2027-06-30","to":"2026-07-10"},{"detected":"2026-09-28","drugId":"trabedersen","nct":"NCT06579196","title":"Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1","phases":["PHASE1","PHASE2"],"sponsor":"University of Nebraska","primaryCompletion":"2028-03","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"hmpl-760","nct":"NCT06601504","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","phases":["PHASE2"],"sponsor":"Hutchmed","primaryCompletion":"2026-05-23","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-28","drugId":"hmpl-760","nct":"NCT06601504","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","phases":["PHASE2"],"sponsor":"Hutchmed","primaryCompletion":"2026-05-23","kind":"primary-completion","from":"2026-05-12","to":"2026-05-23"},{"detected":"2026-09-28","drugId":"shr-8068","nct":"NCT06618664","title":"A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)","phases":["PHASE3"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2026-10","kind":"primary-completion","from":"2026-09","to":"2026-10"},{"detected":"2026-09-28","drugId":"raludotatug-deruxtecan","nct":"NCT06660654","title":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","phases":["PHASE2"],"sponsor":"Daiichi Sankyo","primaryCompletion":"2029-12-30","kind":"primary-completion","from":"2027-09-30","to":"2029-12-30"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT06721013","title":"A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia","phases":["PHASE1","PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-02","kind":"primary-completion","from":"2028-05","to":"2028-02"},{"detected":"2026-09-28","drugId":"nalirifox","nct":"NCT06736717","title":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Kansas Medical Center","primaryCompletion":"2026-07-16","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"nalirifox","nct":"NCT06736717","title":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Kansas Medical Center","primaryCompletion":"2026-07-16","kind":"primary-completion","from":"2026-07","to":"2026-07-16"},{"detected":"2026-09-28","drugId":"atigotatug","nct":"NCT06773910","title":"BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)","phases":["PHASE2"],"sponsor":"SCRI Development Innovations, LLC","primaryCompletion":"2032-05","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"evofosfamide","nct":"NCT06836726","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"University Health Network, Toronto","primaryCompletion":"2028-10-01","kind":"primary-completion","from":"2028-05-27","to":"2028-10-01"},{"detected":"2026-09-28","drugId":"floxuridine","nct":"NCT06888063","title":"Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery","phases":["PHASE2"],"sponsor":"Erasmus Medical Center","primaryCompletion":"2028-09","kind":"primary-completion","from":"2026-09","to":"2028-09"},{"detected":"2026-09-28","drugId":"megestrol-progestins","nct":"NCT06905210","title":"Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris","phases":["PHASE3"],"sponsor":"Eurofarma Laboratorios S.A.","primaryCompletion":"2027-02","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"shr-a1912","nct":"NCT06929624","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","phases":["PHASE3"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2027-03","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"ponsegromab","nct":"NCT06989437","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","phases":["PHASE2","PHASE3"],"sponsor":"Pfizer","primaryCompletion":"2028-01-23","kind":"primary-completion","from":"2028-01-17","to":"2028-01-23"},{"detected":"2026-09-28","drugId":"flotufolastat","nct":"NCT07025369","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2029-01-01","kind":"primary-completion","from":"2026-12-31","to":"2029-01-01"},{"detected":"2026-09-28","drugId":"flot","nct":"NCT07069712","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","phases":["PHASE2"],"sponsor":"AstraZeneca","primaryCompletion":"2027-11-09","kind":"primary-completion","from":"2027-11-03","to":"2027-11-09"},{"detected":"2026-09-28","drugId":"nogapendekin-alfa","nct":"NCT07123727","title":"A Study to Examine Anktiva for the Treatment of COVID-19.","phases":["PHASE2"],"sponsor":"ImmunityBio, Inc.","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-07","to":"2027-03"},{"detected":"2026-09-28","drugId":"metyrapone","nct":"NCT07138274","title":"Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2031-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"trastuzumab-deruxtecan","nct":"NCT07150208","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"aumolertinib","nct":"NCT07183189","title":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","phases":["PHASE3"],"sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","primaryCompletion":"2032-11","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"gecacitinib","nct":"NCT07185633","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","phases":["PHASE2"],"sponsor":"Bin Gu","primaryCompletion":"2027-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"gecacitinib","nct":"NCT07185633","title":"Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease","phases":["PHASE2"],"sponsor":"Bin Gu","primaryCompletion":"2027-10-01","kind":"primary-completion","from":"2026-10-01","to":"2027-10-01"},{"detected":"2026-09-28","drugId":"jnj-79635322","nct":"NCT07266441","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE2"],"sponsor":"Janssen Research & Development, LLC","primaryCompletion":"2027-06-14","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"folfiri","nct":"NCT07271355","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","phases":["PHASE3"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2031-02-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"capox","nct":"NCT07291401","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","phases":["PHASE2"],"sponsor":"Zhongnan Hospital","primaryCompletion":"2027-01-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT07405164","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2034-04-22","kind":"primary-completion","from":"2034-01-14","to":"2034-04-22"},{"detected":"2026-09-28","drugId":"hlx11","nct":"NCT07407920","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-09-30","to":"2028-09-30"},{"detected":"2026-09-28","drugId":"penpulimab","nct":"NCT07419880","title":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2027-01-30","to":"2027-12-31"},{"detected":"2026-09-28","drugId":"raloxifene","nct":"NCT07470606","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","phases":["PHASE2"],"sponsor":"The University of Texas Health Science Center at San Antonio","primaryCompletion":"2030-07","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"raloxifene","nct":"NCT07470606","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","phases":["PHASE2"],"sponsor":"The University of Texas Health Science Center at San Antonio","primaryCompletion":"2030-07","kind":"primary-completion","from":"2030-03","to":"2030-07"},{"detected":"2026-09-28","drugId":"mosunetuzumab","nct":"NCT07548450","title":"Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2034-11","kind":"primary-completion","from":"2034-06","to":"2034-11"},{"detected":"2026-09-28","drugId":"navlimetostat","nct":"NCT07579221","title":"Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2029-08-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"selumetinib","nct":"NCT07619521","title":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-09-08","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"selumetinib","nct":"NCT07619521","title":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-09-08","kind":"primary-completion","from":"2026-10-30","to":"2028-09-08"},{"detected":"2026-09-28","drugId":"tqb2930","nct":"NCT07653685","title":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.","phases":["PHASE1","PHASE2"],"sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","primaryCompletion":"2027-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"pylarify","nct":"NCT07686380","title":"IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-01-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"capox","nct":"NCT07728019","title":"Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2029-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"signatera","nct":"NCT07750158","title":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","phases":["PHASE3"],"sponsor":"Exelixis","primaryCompletion":"2030-04-05","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"telisotuzumab-adizutecan","nct":"NCT07769502","title":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers","phases":["PHASE2"],"sponsor":"AbbVie","primaryCompletion":"2028-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"telisotuzumab-adizutecan","nct":"NCT07769502","title":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers","phases":["PHASE2"],"sponsor":"AbbVie","primaryCompletion":"2028-09","kind":"primary-completion","from":"2028-11","to":"2028-09"},{"detected":"2026-09-28","drugId":"raludotatug-deruxtecan","nct":"NCT07776691","title":"A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2032-03-19","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"nogapendekin-alfa","nct":"NCT07783789","title":"NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis","phases":["PHASE2"],"sponsor":"ImmunityBio, Inc.","primaryCompletion":"2028-05-12","kind":"primary-completion","from":"2027-10-12","to":"2028-05-12"},{"detected":"2026-09-28","drugId":"rc148","nct":"NCT07829549","title":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","phases":["PHASE3"],"sponsor":"RemeGen Co., Ltd.","primaryCompletion":"2031-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"alectinib","nct":"NCT07829744","title":"Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations","phases":["PHASE2"],"sponsor":"Shanghai Zhongshan Hospital","primaryCompletion":"2030-06-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"sacituzumab-tirumotecan","nct":"NCT07829783","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2031-11-17","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"romiplostim","nct":"NCT07829952","title":"Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation","phases":["PHASE2"],"sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","primaryCompletion":"2028-06-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"pirtobrutinib","nct":"NCT07831395","title":"Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2030-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"megestrol","nct":"NCT07831902","title":"Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer","phases":["PHASE3"],"sponsor":"University College, London","primaryCompletion":"2030-12","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"nalirifox","nct":"NCT07831993","title":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","phases":["PHASE2"],"sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","primaryCompletion":"2027-06-30","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"safusidenib","nct":"NCT07832123","title":"Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study","phases":["PHASE2"],"sponsor":"University of Zurich","primaryCompletion":"2029-03","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"imlunestrant","nct":"NCT07832227","title":"Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial","phases":["PHASE2"],"sponsor":"Dana-Farber Cancer Institute","primaryCompletion":"2028-12-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"foundationone-cdx","nct":"NCT07832630","title":"Saruparib in HRDsig+ Solid Tumors","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2029-11-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"in10018","nct":"NCT07833202","title":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","phases":["PHASE3"],"sponsor":"Shanghai Jeyou Pharmaceutical Co., Ltd.","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"surufatinib","nct":"NCT07833241","title":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","phases":["PHASE2"],"sponsor":"Shanghai Zhongshan Hospital","primaryCompletion":"2028-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"trastuzumab-rezetecan","nct":"NCT07833657","title":"Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases","phases":["PHASE2"],"sponsor":"Jiuda Zhao","primaryCompletion":"2030-06","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"trastuzumab-rezetecan","nct":"NCT07836543","title":"Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer","phases":["PHASE2"],"sponsor":"Ming Chen","primaryCompletion":"2029-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"darolutamide","nct":"NCT07838753","title":"A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs","phases":["PHASE2"],"sponsor":"Kokilaben Dheerubhai Ambani Hospital and Research","primaryCompletion":"2029-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"belzutifan","nct":"NCT07840001","title":"Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma","phases":["PHASE2"],"sponsor":"Peter MacCallum Cancer Centre, Australia","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"camizestrant","nct":"NCT07840443","title":"Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma","phases":["PHASE2"],"sponsor":"University Health Network, Toronto","primaryCompletion":"2028-10-26","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"inotuzumab-ozogamicin","nct":"NCT07840976","title":"Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2028-05-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"recombinant-human-endostatin","nct":"NCT07841106","title":"Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases.","phases":["PHASE2"],"sponsor":"Jiangmen Central Hospital","primaryCompletion":"2028-04-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"palonosetron","nct":"NCT07841210","title":"Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2028-01-31","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"zanidatamab","nct":"NCT07841873","title":"Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors","phases":["PHASE2"],"sponsor":"Anhui Provincial Hospital","primaryCompletion":"2028-06-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"octreotide-lanreotide","nct":"NCT07842172","title":"Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms","phases":["PHASE3"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2034-11-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"utidelone","nct":"NCT07842276","title":"Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma","phases":["PHASE2"],"sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","primaryCompletion":"2028-09-20","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"polatuzumab-vedotin","nct":"NCT04594798","title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","phases":["PHASE2"],"sponsor":"University of Rochester","primaryCompletion":"2027-07-31","kind":"primary-completion","from":"2026-07-31","to":"2027-07-31"},{"detected":"2026-09-21","drugId":"tiragolumab","nct":"NCT04665856","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2023-08-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-21","drugId":"thyrotropin-alfa","nct":"NCT05128383","title":"Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids","phases":["PHASE2"],"sponsor":"Beth Israel Deaconess Medical Center","primaryCompletion":"2025-05-19","kind":"results-posted"},{"detected":"2026-09-21","drugId":"trifluridine-tipiracil","nct":"NCT06039202","title":"CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Holy Stone Healthcare Co., Ltd","primaryCompletion":"2030-10","kind":"status","from":"UNKNOWN","to":"SUSPENDED"},{"detected":"2026-09-21","drugId":"trifluridine-tipiracil","nct":"NCT06039202","title":"CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer","phases":["PHASE2"],"sponsor":"Holy Stone Healthcare Co., Ltd","primaryCompletion":"2030-10","kind":"primary-completion","from":"2025-02","to":"2030-10"},{"detected":"2026-09-21","drugId":"intismeran-autogene","nct":"NCT06077760","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","phases":["PHASE3"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2030-06-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-21","drugId":"izalontamab-brengitecan","nct":"NCT06855771","title":"A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)","phases":["PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2028-12-29","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"enfortumab-vedotin","nct":"NCT06906822","title":"PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients","phases":["PHASE2"],"sponsor":"Grupo Español Multidisciplinar de Melanoma","primaryCompletion":"2027-06","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-21","drugId":"iparomlimab-tuvonralimab","nct":"NCT06954116","title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","phases":["PHASE2"],"sponsor":"Tongji Hospital","primaryCompletion":"2028-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2026-09-03","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"TERMINATED"},{"detected":"2026-09-21","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2026-09-03","kind":"primary-completion","from":"2028-12","to":"2026-09-03"},{"detected":"2026-09-21","drugId":"romiplostim","nct":"NCT07421167","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2029-01-18","kind":"primary-completion","from":"2028-05-09","to":"2029-01-18"},{"detected":"2026-09-21","drugId":"sacituzumab-tirumotecan","nct":"NCT07438626","title":"Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-06-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"pucotenlimab","nct":"NCT07497919","title":"A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2029-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"pluvicto","nct":"NCT07650240","title":"Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2030-12-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"isatuximab","nct":"NCT07652905","title":"CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2029-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-21","drugId":"alpelisib","nct":"NCT07679269","title":"Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.","phases":["PHASE2"],"sponsor":"Novartis Pharmaceuticals","primaryCompletion":"2032-03-23","kind":"primary-completion","from":"2031-06-27","to":"2032-03-23"},{"detected":"2026-09-21","drugId":"nalirifox","nct":"NCT07827053","title":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","phases":["PHASE2"],"sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","primaryCompletion":"2029-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"glecirasib","nct":"NCT07827261","title":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"giredestrant","nct":"NCT07827573","title":"A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-11-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"vepugratinib","nct":"NCT07827612","title":"A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-21","drugId":"f182112","nct":"NCT07828522","title":"F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma","phases":["PHASE2"],"sponsor":"Institute of Hematology & Blood Diseases Hospital, China","primaryCompletion":"2027-10-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"vemurafenib","nct":"NCT01709292","title":"Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-09-30","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"pralatrexate","nct":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Jennifer Amengual","primaryCompletion":"2022-09-01","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"pralatrexate","nct":"NCT01947140","title":"Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"Jennifer Amengual","primaryCompletion":"2022-09-01","kind":"results-posted"},{"detected":"2026-09-17","drugId":"flutamide","nct":"NCT03070886","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","phases":["PHASE2","PHASE3"],"sponsor":"NRG Oncology","primaryCompletion":"2025-10-31","kind":"status","from":"COMPLETED","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"olaparib","nct":"NCT04191135","title":"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","phases":["PHASE2"],"sponsor":"Merck Sharp & Dohme LLC","primaryCompletion":"2022-12-15","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"dinutuximab","nct":"NCT04211675","title":"NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab","phases":["PHASE1","PHASE2"],"sponsor":"Nationwide Children's Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"fedratinib","nct":"NCT04282187","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","phases":["PHASE2"],"sponsor":"University of Washington","primaryCompletion":"2027-11-11","kind":"primary-completion","from":"2026-11-11","to":"2027-11-11"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-07-22","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-07-22","kind":"primary-completion","from":"2027-03-31","to":"2026-07-22"},{"detected":"2026-09-17","drugId":"dabrafenib","nct":"NCT04544111","title":"PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09-02","kind":"primary-completion","from":"2026-09-02","to":"2027-09-02"},{"detected":"2026-09-17","drugId":"sonrotoclax","nct":"NCT04771130","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","phases":["PHASE1","PHASE2"],"sponsor":"BeOne Medicines","primaryCompletion":"2028-08-31","kind":"primary-completion","from":"2028-02-08","to":"2028-08-31"},{"detected":"2026-09-17","drugId":"glofitamab","nct":"NCT04889716","title":"CAR-T Followed by Bispecific Antibodies","phases":["PHASE2"],"sponsor":"Abramson Cancer Center at Penn Medicine","primaryCompletion":"2027-12-31","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"abemaciclib","nct":"NCT04921904","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","phases":["PHASE1","PHASE2"],"sponsor":"Baylor Research Institute","primaryCompletion":"2024-12-31","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"abemaciclib","nct":"NCT04921904","title":"Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca","phases":["PHASE1","PHASE2"],"sponsor":"Baylor Research Institute","primaryCompletion":"2024-12-31","kind":"results-posted"},{"detected":"2026-09-17","drugId":"darolutamide","nct":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phases":["PHASE2"],"sponsor":"Bayer","primaryCompletion":"2025-05-30","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"darolutamide","nct":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","phases":["PHASE2"],"sponsor":"Bayer","primaryCompletion":"2025-05-30","kind":"results-posted"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT05197322","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2029-11-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT05197322","title":"NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer","phases":["PHASE2"],"sponsor":"University College, London","primaryCompletion":"2029-11-01","kind":"primary-completion","from":"2026-07-31","to":"2029-11-01"},{"detected":"2026-09-17","drugId":"fulvestrant","nct":"NCT05262400","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-02-26","kind":"primary-completion","from":"2026-08-23","to":"2027-02-26"},{"detected":"2026-09-17","drugId":"dinutuximab","nct":"NCT05421897","title":"Rapid Administration Pilot for Infusing Dinutuximab","phases":["PHASE2"],"sponsor":"Children's Hospital Los Angeles","primaryCompletion":"2028-11","kind":"new-study","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"trifluridine-tipiracil","nct":"NCT05438459","title":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","phases":["PHASE1","PHASE2"],"sponsor":"Kyushu University","primaryCompletion":"2032-03-31","kind":"primary-completion","from":"2028-12-31","to":"2032-03-31"},{"detected":"2026-09-17","drugId":"lorigerlimab","nct":"NCT05475171","title":"Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-06-30","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"olaparib","nct":"NCT05524935","title":"Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-07","kind":"primary-completion","from":"2026-07","to":"2027-07"},{"detected":"2026-09-17","drugId":"giredestrant","nct":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-08-25","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-17","drugId":"giredestrant","nct":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2026-08-25","kind":"primary-completion","from":"2026-08-28","to":"2026-08-25"},{"detected":"2026-09-17","drugId":"apalutamide","nct":"NCT05751941","title":"Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2026-07-04","kind":"primary-completion","from":"2026-07","to":"2026-07-04"},{"detected":"2026-09-17","drugId":"axicabtagene-ciloleucel","nct":"NCT05757219","title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","phases":["PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-06-20","to":"2027-02"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT05759572","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-07-21","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT05759572","title":"Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2026-07-21","kind":"primary-completion","from":"2025-11-01","to":"2026-07-21"},{"detected":"2026-09-17","drugId":"treosulfan","nct":"NCT05807932","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","phases":["PHASE1","PHASE2"],"sponsor":"Heinrich-Heine University, Duesseldorf","primaryCompletion":"2029-04-30","kind":"primary-completion","from":"2026-01-31","to":"2029-04-30"},{"detected":"2026-09-17","drugId":"fruquintinib","nct":"NCT05831891","title":"Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma","phases":["PHASE2"],"sponsor":"RenJi Hospital","primaryCompletion":"2027-10-22","kind":"primary-completion","from":"2026-07-31","to":"2027-10-22"},{"detected":"2026-09-17","drugId":"nalirifox","nct":"NCT05851924","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-09-01","kind":"primary-completion","from":"2026-09-01","to":"2027-09-01"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT05908786","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-08-27","kind":"status","from":"COMPLETED","to":"TERMINATED"},{"detected":"2026-09-17","drugId":"tiragolumab","nct":"NCT05908786","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","phases":["PHASE1","PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2025-08-27","kind":"results-posted"},{"detected":"2026-09-17","drugId":"gemtuzumab-ozogamicin","nct":"NCT05955261","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","phases":["PHASE2"],"sponsor":"St. Jude Children's Research Hospital","primaryCompletion":"2026-12","kind":"status","from":"SUSPENDED","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-04-20","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"foundationone-cdx","nct":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","phases":["PHASE3"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2028-04-20","kind":"primary-completion","from":"2027-02-19","to":"2028-04-20"},{"detected":"2026-09-17","drugId":"arlocabtagene-autoleucel","nct":"NCT06297226","title":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","phases":["PHASE2"],"sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","primaryCompletion":"2026-07-31","kind":"primary-completion","from":"2027-06-30","to":"2026-07-31"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT06394570","title":"Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer","phases":["PHASE1","PHASE2"],"sponsor":"University of Texas Southwestern Medical Center","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2026-07-01","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"bosutinib","nct":"NCT06423911","title":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","phases":["PHASE3"],"sponsor":"Ascentage Pharma Group Inc.","primaryCompletion":"2027-06-30","kind":"primary-completion","from":"2025-12","to":"2027-06-30"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT06495515","title":"Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer","phases":["PHASE2"],"sponsor":"Tianjin Medical University Cancer Institute and Hospital","primaryCompletion":"2025-07-30","kind":"status","from":"UNKNOWN","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"tarlatamab","nct":"NCT06816394","title":"Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)","phases":["PHASE2"],"sponsor":"National Taiwan University Hospital","primaryCompletion":"2027-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"zolbetuximab","nct":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phases":["PHASE3"],"sponsor":"Astellas Pharma Global Development, Inc.","primaryCompletion":"2028-09-30","kind":"primary-completion","from":"2027-03-31","to":"2028-09-30"},{"detected":"2026-09-17","drugId":"cetuximab-sarotalocan","nct":"NCT06943664","title":"Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Roswell Park Cancer Institute","primaryCompletion":"2027-05-01","kind":"status","from":"NOT_YET_RECRUITING","to":"WITHDRAWN"},{"detected":"2026-09-17","drugId":"carfilzomib","nct":"NCT06948084","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2028-02-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"tarlatamab","nct":"NCT07061080","title":"Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab","phases":["PHASE2"],"sponsor":"Grupo Espanol de Tumores Neuroendocrinos","primaryCompletion":"2028-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-17","drugId":"aglatimagene-besadenovec","nct":"NCT07332000","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","phases":["PHASE2"],"sponsor":"Candel Therapeutics, Inc.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-08","to":"2027-02"},{"detected":"2026-09-17","drugId":"tqb6411","nct":"NCT07367516","title":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","primaryCompletion":"2027-02","kind":"primary-completion","from":"2026-09","to":"2027-02"},{"detected":"2026-09-17","drugId":"naxitamab","nct":"NCT07537400","title":"Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5","phases":["PHASE2"],"sponsor":"Shaare Zedek Medical Center","primaryCompletion":"2028-06","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"botensilimab","nct":"NCT07551596","title":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-08-28","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"botensilimab","nct":"NCT07551596","title":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-08-28","kind":"primary-completion","from":"2026-09-30","to":"2029-08-28"},{"detected":"2026-09-17","drugId":"pivekimab-sunirine","nct":"NCT07581002","title":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","phases":["PHASE2","PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2032-06","kind":"primary-completion","from":"2032-05","to":"2032-06"},{"detected":"2026-09-17","drugId":"nalirifox","nct":"NCT07622771","title":"Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","phases":["PHASE2"],"sponsor":"Sun Yat-sen University","primaryCompletion":"2028-06-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"lurbinectedin","nct":"NCT07625644","title":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","phases":["PHASE3"],"sponsor":"SystImmune Inc.","primaryCompletion":"2030-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT07667335","title":"Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2029-07-16","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"nintedanib","nct":"NCT07679893","title":"Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis","phases":["PHASE2"],"sponsor":"Mannkind Corporation","primaryCompletion":"2027-12-30","kind":"primary-completion","from":"2028-01-30","to":"2027-12-30"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07718854","title":"Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","phases":["PHASE2"],"sponsor":"Tufts Medical Center","primaryCompletion":"2036-09","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07718854","title":"Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer","phases":["PHASE2"],"sponsor":"Tufts Medical Center","primaryCompletion":"2036-09","kind":"primary-completion","from":"2032-03","to":"2036-09"},{"detected":"2026-09-17","drugId":"palifermin","nct":"NCT07775313","title":"Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM","phases":["PHASE1","PHASE2"],"sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","primaryCompletion":"2031-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"ENROLLING_BY_INVITATION"},{"detected":"2026-09-17","drugId":"ql1706","nct":"NCT07776080","title":"Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","phases":["PHASE2"],"sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","primaryCompletion":"2027-10-01","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"azd5335","nct":"NCT07816666","title":"Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer","phases":["PHASE3"],"sponsor":"AstraZeneca","primaryCompletion":"2028-09-26","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"trastuzumab-rezetecan","nct":"NCT07817654","title":"Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure","phases":["PHASE2"],"sponsor":"Henan Cancer Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"envafolimab","nct":"NCT07818304","title":"SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC","phases":["PHASE2"],"sponsor":"The First People's Hospital of Lianyungang","primaryCompletion":"2028-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sctb35","nct":"NCT07819188","title":"SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Sinocelltech Ltd.","primaryCompletion":"2028-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"epcoritamab","nct":"NCT07819214","title":"Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI","phases":["PHASE2"],"sponsor":"University of California, Irvine","primaryCompletion":"2028-10","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07819578","title":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","phases":["PHASE2"],"sponsor":"Shaodong Hong","primaryCompletion":"2028-12-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"daraxonrasib","nct":"NCT07819838","title":"Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations","phases":["PHASE1","PHASE2"],"sponsor":"Children's Oncology Group","primaryCompletion":"2032-04-09","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"megestrol-progestins","nct":"NCT07820358","title":"Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer","phases":["PHASE2"],"sponsor":"The Methodist Hospital Research Institute","primaryCompletion":"2028-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hs-20089","nct":"NCT07821606","title":"Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer","phases":["PHASE3"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2029-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"telisotuzumab-adizutecan","nct":"NCT07821684","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"AbbVie","primaryCompletion":"2031-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"enfortumab-vedotin","nct":"NCT07822373","title":"A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer","phases":["PHASE2"],"sponsor":"University of Utah","primaryCompletion":"2034-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"sacituzumab-tirumotecan","nct":"NCT07823270","title":"Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"Hebei Medical University Fourth Hospital","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"inca33890","nct":"NCT07823322","title":"A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy","phases":["PHASE2"],"sponsor":"Incyte Corporation","primaryCompletion":"2029-05-14","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"ql2107","nct":"NCT07823491","title":"Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall","phases":["PHASE3"],"sponsor":"Ohio State University Comprehensive Cancer Center","primaryCompletion":"2028-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"radioactive-iodine","nct":"NCT07823686","title":"Tracheal Replacement Using A Cryopreserved Aortic Allograft For R0 Resection In Locally Advanced Thyroid Cancer (TRITON 02 Tracheal Replacement In ThyrOid caNcer)","phases":["PHASE2"],"sponsor":"Assistance Publique - Hôpitaux de Paris","primaryCompletion":"2030-08-27","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hpv-quadrivalent-vaccine","nct":"NCT07824310","title":"Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children","phases":["PHASE3"],"sponsor":"PT Bio Farma","primaryCompletion":"2026-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hlx22","nct":"NCT07824869","title":"A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients","phases":["PHASE2"],"sponsor":"Shanghai Henlius Biotech","primaryCompletion":"2028-03-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"hs-20093","nct":"NCT07824882","title":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","phases":["PHASE2"],"sponsor":"Hansoh BioMedical R&D Company","primaryCompletion":"2028-03-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"avutometinib-defactinib","nct":"NCT07824960","title":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","phases":["PHASE1","PHASE2"],"sponsor":"University of Virginia","primaryCompletion":"2029-04","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"cevostamab","nct":"NCT07825064","title":"Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma","phases":["PHASE2"],"sponsor":"Hoffmann-La Roche","primaryCompletion":"2029-04-13","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-17","drugId":"datopotamab-deruxtecan","nct":"NCT07825753","title":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2027-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-17","drugId":"dalpiciclib","nct":"NCT07826052","title":"Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer","phases":["PHASE2"],"sponsor":"Fudan University","primaryCompletion":"2031-09-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"dabrafenib","nct":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phases":["PHASE1","PHASE2"],"sponsor":"Pediatric Brain Tumor Consortium","primaryCompletion":"2026-10-01","kind":"primary-completion","from":"2026-03-31","to":"2026-10-01"},{"detected":"2026-09-11","drugId":"ipilimumab","nct":"NCT04464759","title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","phases":["PHASE1","PHASE2"],"sponsor":"Ravi Amaravadi, MD","primaryCompletion":"2026-11-13","kind":"primary-completion","from":"2026-07-31","to":"2026-11-13"},{"detected":"2026-09-11","drugId":"cabozantinib","nct":"NCT04820179","title":"Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer","phases":["PHASE2"],"sponsor":"University of Arizona","primaryCompletion":"2026-02-20","kind":"results-posted"},{"detected":"2026-09-11","drugId":"imlunestrant","nct":"NCT04923542","title":"SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases","phases":["PHASE1","PHASE2"],"sponsor":"H. Lee Moffitt Cancer Center and Research Institute","primaryCompletion":"2026-11-05","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"sacituzumab-govitecan","nct":"NCT05186974","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","phases":["PHASE2"],"sponsor":"Gilead Sciences","primaryCompletion":"2027-03","kind":"primary-completion","from":"2026-09","to":"2027-03"},{"detected":"2026-09-11","drugId":"epcoritamab","nct":"NCT05201248","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Genmab","primaryCompletion":"2026-09","kind":"primary-completion","from":"2025-04","to":"2026-09"},{"detected":"2026-09-11","drugId":"lurbinectedin","nct":"NCT05229588","title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","phases":["PHASE2"],"sponsor":"HonorHealth Research Institute","primaryCompletion":"2025-08-04","kind":"results-posted"},{"detected":"2026-09-11","drugId":"inavolisib","nct":"NCT05306041","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","phases":["PHASE2"],"sponsor":"GBG Forschungs GmbH","primaryCompletion":"2027-01","kind":"primary-completion","from":"2026-10","to":"2027-01"},{"detected":"2026-09-11","drugId":"amivantamab","nct":"NCT05845450","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2027-05","kind":"primary-completion","from":"2026-05","to":"2027-05"},{"detected":"2026-09-11","drugId":"revumenib","nct":"NCT06229912","title":"A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-01","kind":"primary-completion","from":"2026-12-01","to":"2028-12-01"},{"detected":"2026-09-11","drugId":"mosunetuzumab","nct":"NCT06492837","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","phases":["PHASE2"],"sponsor":"Fondazione Italiana Linfomi - ETS","primaryCompletion":"2028-09-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"sotorasib","nct":"NCT06582771","title":"A Study of Sotorasib in People With Non-Small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2027-08","kind":"primary-completion","from":"2026-08","to":"2027-08"},{"detected":"2026-09-11","drugId":"relatlimab-nivolumab","nct":"NCT06708949","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-15","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"relatlimab-nivolumab","nct":"NCT06708949","title":"A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)","phases":["PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2028-12-15","kind":"primary-completion","from":"2026-12-15","to":"2028-12-15"},{"detected":"2026-09-11","drugId":"lisocabtagene-maraleucel","nct":"NCT07098364","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","phases":["PHASE1","PHASE2"],"sponsor":"Fred Hutchinson Cancer Center","primaryCompletion":"2030-10-04","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-11","drugId":"degarelix","nct":"NCT07335796","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2030-01-09","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-11","drugId":"penpulimab","nct":"NCT07381075","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2028-12-31","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"penpulimab","nct":"NCT07381075","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"sponsor":"West China Hospital","primaryCompletion":"2028-12-31","kind":"primary-completion","from":"2028-10-01","to":"2028-12-31"},{"detected":"2026-09-11","drugId":"bicalutamide","nct":"NCT07593079","title":"Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer","phases":["PHASE2"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2027-11-14","kind":"primary-completion","from":"2027-08-14","to":"2027-11-14"},{"detected":"2026-09-11","drugId":"olomorasib","nct":"NCT07814417","title":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","phases":["PHASE2"],"sponsor":"Eli Lilly and Company","primaryCompletion":"2028-11","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"sacituzumab-tirumotecan","nct":"NCT07815197","title":"Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer","phases":["PHASE2"],"sponsor":"Latin American Cooperative Oncology Group","primaryCompletion":"2028-03","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-11","drugId":"dalpiciclib","nct":"NCT07815522","title":"Abiraterone With Dalpiciclib in Salivary Gland Carcinoma","phases":["PHASE2"],"sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","primaryCompletion":"2028-10-01","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"enfortumab-vedotin","nct":"NCT07815665","title":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","phases":["PHASE2","PHASE3"],"sponsor":"Summit Therapeutics","primaryCompletion":"2030-10-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-11","drugId":"crizotinib","nct":"NCT07816380","title":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phases":["PHASE3"],"sponsor":"Guangzhou JOYO Pharma Co., Ltd","primaryCompletion":"2028-12-30","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"inotuzumab-ozogamicin","nct":"NCT03104491","title":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","phases":["PHASE1","PHASE2"],"sponsor":"Leland Metheny","primaryCompletion":"2026-11","kind":"primary-completion","from":"2025-11","to":"2026-11"},{"detected":"2026-09-10","drugId":"cpx-351","nct":"NCT04061239","title":"Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML","phases":["PHASE2"],"sponsor":"GWT-TUD GmbH","primaryCompletion":"2026-08-07","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-10","drugId":"cpx-351","nct":"NCT04061239","title":"Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML","phases":["PHASE2"],"sponsor":"GWT-TUD GmbH","primaryCompletion":"2026-08-07","kind":"primary-completion","from":"2026-03","to":"2026-08-07"},{"detected":"2026-09-10","drugId":"tiragolumab","nct":"NCT04958811","title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","phases":["PHASE2"],"sponsor":"Georgetown University","primaryCompletion":"2026-11","kind":"primary-completion","from":"2026-07","to":"2026-11"},{"detected":"2026-09-10","drugId":"megestrol-progestins","nct":"NCT05316935","title":"GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients","phases":["PHASE2","PHASE3"],"sponsor":"Xiaojun Chen","primaryCompletion":"2028-03-30","kind":"primary-completion","from":"2026-03-30","to":"2028-03-30"},{"detected":"2026-09-10","drugId":"luspatercept","nct":"NCT05664737","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia","phases":["PHASE2"],"sponsor":"Bristol-Myers Squibb","primaryCompletion":"2027-07-16","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-10","drugId":"megestrol-progestins","nct":"NCT06379113","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","phases":["PHASE2","PHASE3"],"sponsor":"Xiaojun Chen","primaryCompletion":"2028-03-30","kind":"primary-completion","from":"2026-03-30","to":"2028-03-30"},{"detected":"2026-09-10","drugId":"talquetamab","nct":"NCT06572605","title":"External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease","phases":["PHASE1","PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2030-01-18","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-09-10","drugId":"serplulimab","nct":"NCT06576921","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","phases":["PHASE2"],"sponsor":"Xijing Hospital","primaryCompletion":"2026-08-10","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-10","drugId":"serplulimab","nct":"NCT06576921","title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","phases":["PHASE2"],"sponsor":"Xijing Hospital","primaryCompletion":"2026-08-10","kind":"primary-completion","from":"2026-05-31","to":"2026-08-10"},{"detected":"2026-09-10","drugId":"ivonescimab","nct":"NCT07602855","title":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","phases":["PHASE1","PHASE2"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-06-21","kind":"primary-completion","from":"2029-07-05","to":"2029-06-21"},{"detected":"2026-09-10","drugId":"izalontamab-brengitecan","nct":"NCT07640789","title":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)","phases":["PHASE3"],"sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","primaryCompletion":"2030-12","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-10","drugId":"sacituzumab-tirumotecan","nct":"NCT07811752","title":"Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer","phases":["PHASE2"],"sponsor":"Shanghai Chest Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-09-10","drugId":"sonrotoclax","nct":"NCT07812246","title":"Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial","phases":["PHASE2"],"sponsor":"City of Hope Medical Center","primaryCompletion":"2028-08-13","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"pirtobrutinib","nct":"NCT07812493","title":"Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement","phases":["PHASE2"],"sponsor":"Pengpeng Xu","primaryCompletion":"2028-09-01","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-10","drugId":"epcoritamab","nct":"NCT07814001","title":"Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy","phases":["PHASE2"],"sponsor":"The Lymphoma Academic Research Organisation","primaryCompletion":"2028-07","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"trastuzumab-emtansine","nct":"NCT02675829","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","phases":["PHASE2"],"sponsor":"Memorial Sloan Kettering Cancer Center","primaryCompletion":"2026-09-04","kind":"primary-completion","from":"2027-02","to":"2026-09-04"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-09-09","drugId":"optune","nct":"NCT02847559","title":"Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","phases":["PHASE2"],"sponsor":"Northwestern University","primaryCompletion":"2025-08-11","kind":"primary-completion","from":"2026-09","to":"2025-08-11"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT03803553","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","phases":["PHASE3"],"sponsor":"Massachusetts General Hospital","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"relatlimab-nivolumab","nct":"NCT04080804","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","phases":["PHASE2"],"sponsor":"Dan Zandberg","primaryCompletion":"2026-04-13","kind":"primary-completion","from":"2027-10-01","to":"2026-04-13"},{"detected":"2026-09-09","drugId":"brentuximab-vedotin","nct":"NCT05039073","title":"Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2027-11-30","kind":"primary-completion","from":"2026-11-30","to":"2027-11-30"},{"detected":"2026-09-09","drugId":"autogene-cevumeran","nct":"NCT05968326","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","phases":["PHASE2"],"sponsor":"Genentech, Inc.","primaryCompletion":"2031-01-01","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"encorafenib","nct":"NCT06578559","title":"Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC","phases":["PHASE2"],"sponsor":"Gruppo Oncologico del Nord-Ovest","primaryCompletion":"2026-05-12","kind":"primary-completion","from":"2026-08-01","to":"2026-05-12"},{"detected":"2026-09-09","drugId":"lutathera","nct":"NCT06955169","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","phases":["PHASE2"],"sponsor":"RTOG Foundation, Inc.","primaryCompletion":"2029-08","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"disitamab-vedotin","nct":"NCT06966453","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Pfizer","primaryCompletion":"2027-10-25","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","phases":["PHASE3"],"sponsor":"Amgen","primaryCompletion":"2029-01-04","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-09","drugId":"tarlatamab","nct":"NCT07016230","title":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)","phases":["PHASE2"],"sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","primaryCompletion":"2027-05-18","kind":"primary-completion","from":"2026-10-18","to":"2027-05-18"}]}